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1Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder. Most 
symptoms and signs can be ascribed to a dopamine deficiency, resulting from 
progressive neuronal loss in the substantia nigra. Particularly later in the course of 
the disease, additional non-dopaminergic lesions arise that can also contribute to 
the symptoms. The estimated prevalence is 0.5-1% above the age of 60 years and 
more than 4% above 80 years. In the Netherlands, approximately 5.000 people 
are newly diagnosed with PD every year.1 The diagnosis is made based on the UK 
Brain Bank Criteria which demand the presence of bradykinesia with either rigidity, 
tremor or postural instability (Box 1).2 Although motor symptoms play a key role 
in diagnosing the disease, it is becoming increasingly clear that PD is not only a 
movement disorder. The involvement of noradrenergic, serotonergic, cholinergic 
and other neurotransmitter systems leads to the presence of a broad spectrum of 
non-motor symptoms in PD. In many cases these symptoms can even precede 
the appearance of motor symptoms.3-10 A wide variety of non-motor symptoms can 
be present, such as autonomic dysfunction, cognitive problems, mood disorders 
and sleep problems.4,6-8 The last decades it has become evident that the impact 
of these non-motor symptoms is a major determinant of the patient’s quality of 
life, even more so than the motor problems.11-13 Therefore, timely recognition and 
adequate treatment of these problems is very important for patients with PD. This 
thesis focuses on one specific non-motor feature that is both common and disabling 
for affected patients: disorders of sleep.
Box 1. Motor symptoms of Parkinson’s disease 
Akinesia  
(slowness of initiation of voluntary movements or poverty of movements and 
movements that are smaller than attended) 
 
Accompanied with at least one of the following signs:
Muscle rigidity  
(increased muscle tone that can be felt during passive movement)
4-6 Hz rest tremor
Postural instability
12
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1Box 2. Different sleep stages and their characteristics 
Figure 1.  Typical hypnogram of a healthy subject
PSG and clinical characteristics
Non-REM sleep
Stage 1  · EEG: alpha rhythm of wake drops out. A more 
slow end mixed pattern of amplitudes appears
 · The muscles are active and the eyes roll slowly
Stage 2  · EEG: theta rhythm; with incidence of sleep 
spindles and K-complexes
 · No eye movements, muscle tone is preserved
Stage 3
(slow wave sleep)
 · EEG: delta activity, high amplitude waves at less 
than 3.5 Hz
 · Sleeper is less responsive to the environment
REM sleep
(dream sleep)  · EEG: mixed frequency EEG similar to stage 1 with 
saw tooth waves
 · Chin EMG tone very low compared to tone in 
other sleep stages
 · Rapid eye movements
Sleep 
Normal sleep
Sleep is a universal phenomenon across species. Sleep is important for normal 
functioning during the day. During sleep the body relaxes and certain experiences 
of the day are stored as memory. Reduced hours of sleep or bad sleep quality re-
sult in fatigue during the day, but can also lead to an increased risk of cardiovascu-
lar problems.14,15 Sleep can be measured with polysomnography (PSG), which is a 
combination of brain activity (electroencephalography, EEG), muscle activity (elec-
tromyography, EMG), eye movements (electrooculography, EOG) and associated 
cardiorespiratory parameters.16 The sleep cycle can be divided in 4 stages. Stage 1, 
2 and 3 are non-rapid eye movement (non- REM) sleep, the last stage is REM sleep. 
Box 2 shows the different sleep stages and their characteristics measured with 
PSG.16 During one night several subsequent cycles of stage 1, stage 2, stage 3 and 
REM sleep are present. During the first cycles stage 3 sleep is more pronounced, at 
the end of the night REM sleep is more prominent (Figure 1).16
The amount of sleep a person needs is individually different. In general, optimal sleep 
duration is somewhere between 5 and 10 hours per night. Sleep structure changes 
over a persons’ life. In a newly born child, during the first couple of months the dis-
tribution between wake, non-REM sleep and REM sleep is almost equal. Moreover 
sleep is spread over 24 hours. During childhood sleep consolidates in the nocturnal 
period. With increasing age the amount of wake increases and the amount of REM 
sleep decreases. Elderly subjects have more fragmented sleep.17,18
Abnormal sleep
Having a bad night of sleep once in a while is, although troublesome, not uncommon. 
Several bad nights in a row, however, could indicate a sleep disorder. Disrupted night 
time sleep can cause daytime sleepiness and fatigue and therefore influence daytime 
functioning.14,15 Sleep can be disrupted by many external factors such as noise, stress 
and pain. Sleep disorders caused by pathophysiological processes can also be pres-
ent. Sleep problems may have a substantial influence on quality of life, sometimes 
leading to a diminished participation in social events or absence from work.15
Sleep disorders are classified according to the International Classification of Sleep 
Disorders, of which a second edition was published in 2005 and a third edition has 
recently been made available.19 Box 3 describes the most common types of sleep 
disorders with some examples. 
REM
23.3022.30 00.30 01.30 02.30 03.30 04.30 05.30 06.30
AWK
N1
N2
N3
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1Sleep in Parkinson’s disease
Already in 1817 James Parkinson wrote about sleep in his classic “An essay on the 
shaking palsy”. Describing the patients he used phrases like “in this stage, the sleep 
becomes much disturbed”, “but even when exhausted nature seizes a small portion 
of sleep” and “the trembling would increase until it awakened him: when he always 
was in a state of agitation and alarm”.20 In the years following this essay, sleep as 
a PD-related problem was underexposed, in fact like any of the other non-motor 
symptoms. In the last decades, however, the role of sleep problems as an important 
problem in PD has been increasingly recognized. Up to 90% of PD patients com-
plain of having sleep problems.21-24 In PD, sleep can be disrupted by a wide variety 
of causes. All “generic” sleep disorders can be present in PD patients, and some are 
particularly prevalent in this population. 
Nocturnal motor symptoms in PD
Although sleep disorders are considered to be among the non-motor symptoms in 
PD, the motor symptoms of the disease itself can also cause disrupted sleep. In clin-
ical practice it is assumed that the motor symptoms of PD have a negative influence 
on sleep quality. Although tremor usually diminishes in stage 1 sleep, if persistent 
it could prevent a person from falling asleep.22 Nocturnal hypokinesia could lead to 
difficulties turning around in bed which could cause sleep initiation or sleep main-
tenance problems.25-28 The precise mechanism behind this impaired bed mobility 
in PD is not clear. The complaint is often referred to as “nocturnal hypokinesia”, but 
rigidity, pain and overall muscle weakness could also be a part of the problem.29,30 
In clinical practice if a patient complains of having difficulty turning around in bed, 
nocturnal dopaminergic treatment is often started. However, scientific proof wheth-
er there is an actual relation between complaints of impaired mobility, number of 
body position changes and sleep quality is lacking. Previous studies have suggest-
ed that impaired bed mobility negatively influences sleep quality. PD patients were 
compared with healthy controls, showing that in a cohort with sleep maintenance 
problems, subjective presence of turning problems were more frequent in the PD 
group.27 This suggest that difficulty turning interferes with sleep. However, these re-
sults could also be explained by a co-occurrence of both insomnia and impaired 
bed mobility in PD, without a causal relation. Other studies report increased noctur-
nal activity levels in PD patients compared to controls.24,31,32 Possible explanations for 
this are sleep fragmentation leading to more wake or presence of specific nocturnal 
motor disorders such as REM sleep behavior disorder.
Box 3. Different types of sleep disorders
Types of sleep disorders
Insomnia 
(problems initiating or maintaining sleep)
 · Adjustment insomnia
 · Psychophysiological insomnia
 · Inadequate sleep behavior
Sleep related breathing disorders
 · Obstructive sleep apnea syndrome
 · Central sleep apnea syndrome
Hypersomnias
(excessive daytime sleepiness)
 · Idiopathic hypersomnia
 · Narcolepsy
Circadian rhythm disorders 
(sleep disorders affecting the biological clock)
 · Delayed sleep phase disorder
 · Advanced sleep phase disorder
 · Jet lag disorder
Parasomnias
(abnormal movements during sleep)
 · Confusional arousals
 · Sleep walking
 · REM sleep behavior disorder
Sleep related movement disorders 
(abnormal movements during sleep)
 · Restless legs syndrome
 · Periodic limb movement disorder
16
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1Outline of this thesis
Chapter 2.1 contains a detailed and comprehensive introduction about the latest 
developments in the recognition and diagnosis of the different sleep disorders that 
can be present in PD. We developed a structured, easy-to-use flow chart which can 
be used by every movement disorder specialist as an aid in the clinical detection of 
sleep problems in these patients. Furthermore we make suggestions with regard 
to the additional tests that can be done as part of the diagnostic trajectory, and offer 
recommendations when a patient should be referred to a sleep medicine center.
Although sleep disorders receive increasing attention in both clinical practice and 
in science, the actual importance of sleep disorders compared to other PD-related 
complaints is underexposed. Are sleep problems a reason to search for medical 
attention? In Chapter 2.2 we address this question. By using a subjective priority 
list we put sleep disorders into perspective with other symptoms and daily limits in 
PD. We studied a cohort of consecutive PD patients who were referred for problems 
other than sleep to our tertiary referral center. Prior to their visit, patients ranked their 
individual clinical priorities, indicating the most problematic domains for which they 
preferably requested medical attention. In addition we studied if presence of a sleep 
problem was a reason to put sleep on the priority list.
The second half of the thesis focuses on nocturnal movements in PD. 
Chapter 3 deals with difficulties in movement during the night. As suggested, com-
plaints of having difficulty turning around in bed could theoretically lead to bad sleep 
quality. This hypothesis was first tested in Chapter 3.1 by using sleep questionnaires. 
We studied the association between subjective complaints of impaired bed mobility 
in PD patients and sleep quality. Therefore we compared subjective sleep quality 
in PD patients with and without impaired bed mobility. Second, in Chapter 3.2 we 
studied whether subjective complaints of impaired bed mobility indeed lead to a 
decreased number of nocturnal movements. We objectified the complaint by mea-
suring actual body position changes in both PD patients with and without impaired 
bed mobility. Furthermore we studied the influences of both the presence of sub-
jective impaired bed mobility and the actual number of body positions changes on 
objective sleep parameters such as sleep efficiency and total sleep time. 
Chapter 4 covers nocturnal movements in the pre-motor phase of PD. Nocturnal 
hypokinesia could lead to a decrease in axial movements during the night. Next to 
Whether subjective problems of having difficulty turning around in bed indeed lead 
to a decreased number of nocturnal movements has not been proven yet. Further-
more the influence of subjective and objective impaired bed mobility is not known. 
For clinical practice, however, an answer to these questions is important, especially 
in the choice of treatment.
In this thesis we addressed this underexposed part of sleep in PD. By studying both 
the subjective complaints as well as the objective signs of nocturnal movements 
and their influence on sleep parameters we addressed most of these questions. 
Furthermore, we studied if possible changes in nocturnal movement could serve as 
a pre-clinical marker in the early detection of PD. 
18
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Introduction
Sleep disorders are among the most common non-motor symptoms in Parkinson’s 
disease (PD), with an estimated prevalence of 65% to more than 95%.1-4 Sleep dis-
orders negatively affect the quality of life.5-7 Fortunately, specific treatment options 
are available, but adequate treatment requires a precise and timely diagnosis of the 
specific sleep disorder at hand. This recognition and diagnosis remains challenging 
in everyday clinical practice, because of the wide variety and intricate combinations 
of sleep disorders in PD. 
The whole gamut of sleep disorders may occur in PD, including excessive daytime 
sleepiness, insomnia, nocturnal motor symptoms and sleep-related breathing dis-
orders. Three main groups of causes can be identified. Sleep problems can be a pri-
mary disease symptom, caused by neuronal degeneration in sleep-regulating brain 
regions. An example is EDS in cognitive declined patients.8 Second, sleep may be 
disrupted by other symptoms of PD, such as nocturnal motor symptoms (e.g. diffi-
culty turning in bed) or autonomic dysfunction (e.g. nocturia). And third, many drugs 
used in the treatment of PD can affect sleep.1,9-12 For example, selegiline –which is 
metabolized to methamphetamine and amphetamine- may cause insomnia.13
Most sleep disturbances can be diagnosed and treated by the movement disorders 
specialist. However, the diversity and complex origin of sleep disorders in PD may 
complicate the diagnostic trajectory. Ancillary investigations are needed occasion-
ally, including polysomnographic recordings. In specific cases, the diagnostic and 
therapeutic help of a sleep medicine specialist can be useful. 
To adequately treat sleep disorders in PD, an accurate diagnosis is crucial. Treatment 
options are diverse and depend on the specific sleep disorder(s) that are present. In 
Table 1, some of the most common sleep disorders are highlighted, together with 
specifically tailored treatment options. For more elaborate details on the treatment of 
sleep disorders in PD, we refer to previously published reviews.14,15
The purpose of this paper is twofold. We highlight the most important recent devel-
opments that have clinical relevance for the (differential) diagnosis of sleep disorders 
in PD. In addition – and based on this new knowledge – we provide a practical, easily 
applicable approach to the recognition and diagnosis of sleep disorders in PD and 
atypical parkinsonian syndromes. 
Abstract
Sleep disturbances are among the most frequent and incapacitating non-motor 
symptoms of Parkinson’s disease (PD), and are increasingly recognized as an 
important determinant of impaired quality of life. Here we review several recent 
developments regarding the recognition and diagnosis of sleep disorders in PD. In 
addition, we provide a practical and easily applicable approach to the diagnostic 
process, as a basis for tailored therapeutic interventions. This includes a stepwise 
scheme that guides the clinical interview and subsequent ancillary investigations. 
In this scheme, the various possible sleep disorders are arranged not in order of 
prevalence, but in a “differential diagnostic” order. We also provide recommendations 
for the use of sleep registrations such as polysomnography. Furthermore, we point 
out when a sleep specialist could be consulted to provide additional diagnostic 
and therapeutic input. This structured approach facilitates early detection of sleep 
disturbances in PD, so treatment can be initiated promptly.
2928
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Table 2.  Key elements of the sleep history for PD patientsTable 1.  Therapeutic options of the most common sleep disorders in PD
Ex
ce
ss
iv
e 
 
da
yt
im
e 
sl
ee
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ne
ss
Disrupted 
nocturnal sleep
 · Improve nocturnal sleep
Medication 
side effect
 · If possible discontinue or  
change medication
Primary 
hypersomnia
 · Stimulant medication
 · modafinil16
 · methylphenidate  (no controlled studies)
N
oc
tu
rn
al
 
m
ot
or
 
sy
m
pt
om
s
Nocturnal “off”  · slow release levodopa preparation17
 · continuous dopaminergic stimulation 
(apomorfine, rotigotine, duodopa)18,19
Restless legs syndrome 
Periodic limb movement 
disorder
 · increase nighttime dose of  
dopaminergic medication20
 · opiate20
 · gabapentin20
REM sleep behavior 
disorder
 · clonazepam21
 · melatonin22
Sl
ee
p 
re
la
te
d 
br
ea
th
in
g
di
so
rd
er
s Obstructive 
sleep apnea
 · continuous positive airway pressure14
Nocturnal 
stridor
 · continuous positive airway pressure23-25
 · tracheotomy26
Screening questions
 · sleep onset insomnia (sleep latency > 30 minutes)
 · frequent awakenings
 · non-restorative sleep (unrefreshed in the morning, tiredness/sleepiness just  
after awakening)
 · daytime sleepiness (either unwanted sleep episodes or napping)
When a sleep disorder is suspected
 · check habitual bedtimes, sleep latency, number and duration of awakenings,  
total sleep time
 · screening for nocturnal motor symptoms including “off” symptoms and RBD
 · screening for nocturia, nocturnal pain
 · screening for sleep related breathing disorders 
 · screening for mood and anxiety disorders, hallucinations
 · daytime sleepiness: frequency, warning signs, driving
 · detailed medication schedule, relation to sleep symptoms
Further questioning:
Sleep relating breathing disorders
 · snoring, witnessed apneas, nocturnal stridor, daytime stridor
 · nocturia, night sweats, dry mouth in the morning, morning headaches
REM Sleep Behavior Disorder
 · sleep talking, shouting, swearing
 · gross body movements resembling “dream enactment” (often aggressive)
Restless Legs Syndrome
 · check diagnostic criteria (see Table 3)
Nocturia
 · frequency, volume, urologic symptoms during the day
 · fluid intake in the evening, caffeine and alcohol use, medication such as diuretics
Primary insomnia
 · circumstances around onset, sleep hygiene, extending bed times “to try and 
catch some sleep”
 · worrying when lying awake, frequently checking the clock
 · mood and other co-morbid disorders
Excessive daytime sleepiness
 · frequency and duration of unintentional sleep episodes
 · circumstances, warning signs, relation with dopaminergic medication
 · driving, effect of planned naps
Sleep diagnostics
The sleep history
The clinical interview remains the single most important diagnostic instrument. Al-
though sleep disorders are common in PD, they are not always mentioned sponta-
neously by the patient, as was recently shown.27 A few quick screening questions, 
probing both nocturnal sleep and daytime sleepiness (see Table 2), should be asked 
on a regular basis in every PD patient. When these questions raise suspicion of a 
relevant sleep disorder, a structured history is the essential starting point of the diag-
nostic trajectory. Table 2 describes the various topics that should be covered in such 
a comprehensive sleep history. 
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an objective diagnosis is needed (e.g. in relation to driving) or when there is difficulty 
separating sleepiness from related complaints of fatigue.
Diagnostic strategy
Most reviews on sleep disorders in PD are organized based on the (presumed) 
pathophysiology, but lack a clear structure that can aid in the differential diagnosis. 
Adopting a systematic way of thinking about disturbed sleep facilitates the clinical 
interview and reduces the risk of missing sleep disorders. In Figure 1, we have put 
the various PD-related sleep disorders into a flowchart, which can be followed in 
every patient. The order is based on differential diagnostic grounds, and is not relat-
ed to prevalence or severity. The various disorders are categorized into “excessive 
daytime sleepiness” and “disturbed nocturnal sleep”. The latter category is in turn 
subdivided into “nocturnal motor symptoms”, “sleep-related breathing disorders” 
and “other causes of insomnia”.
The diagnostic process starts with determining whether daytime sleepiness is pres-
ent. If so, one should decide if disturbed nocturnal sleep is a likely culprit, in which 
case the flowchart should be followed in that direction. If not, side-effects of med-
ication and primary hypersomnias remain possible causes for excessive daytime 
sleepiness. Nocturnal motor symptoms are the primary cause to be checked when 
nighttime sleep is disturbed. Sleep-related breathing disorders should then be 
checked for. What remains are several other causes of insomnia, with their associat-
ed diagnostic trajectory. Importantly, one should always consider the fact that more 
than one sleep disorder can be present. 
Table 3 explains the various categories of the flowchart, with the associated diag-
nostic tools. The table further shows in which cases the help of a sleep medicine 
specialist could be considered for additional diagnostic and therapeutic input.
Sleep questionnaires
Sleep questionnaires can help to collect data in a standard fashion, although they are 
no substitute for a personal clinical interview. In the past years, several sleep ques-
tionnaires have been developed to identify sleep disorders in PD. A recent study 
of The Sleep Scale Task Force reviewed these scales and made recommendations 
for their use.28 The Pittsburgh Sleep Quality Index (PSQI) is a well-validated mea-
sure of nocturnal sleep quality and severity of nighttime sleep disturbances.29 The 
Parkinson’s Disease Sleep Scale (PDSS) is a more general scale which specifically 
rates sleep problems in PD.30 The Epworth Sleepiness Scale (ESS) is recommend-
ed to screen for excessive daytime sleepiness and to rate its severity.31 A specific 
screening for sleep attacks is provided by The Inappropriate Sleep Composite Score 
(ISCS).32 Nighttime sleep problems and excessive daytime sleepiness are both part 
of the Scales for Outcomes in Parkinson’s Disease SLEEP (SCOPA-SLEEP), but this 
scale has not yet been validated against other – objective – sleep measures.33
The Sleep Scale Task Force has also commented on the fact that many available 
sleep questionnaires offer an overall rating of the severity of night- or daytime sleep 
problems, but are not intended to diagnose a specific sleep disorder. Recently, the 
PDSS has been revised and updated to tackle this issue. The PDSS-2 now screens 
for sleep disorders that are common in PD, such as restless syndrome, nocturnal 
hypokinesia and/or pain and sleep apnea.34 The PDSS-2 was validated using a 
semi-structured interview, but a validation against objective measurements such as 
polysomnography has not yet been performed. 
Sleep registrations
A number of neurophysiological studies allow for the assessment of sleep archi-
tecture and the detection of nocturnal sleep disorders as well as excessive daytime 
sleepiness, but these sleep registrations should always be interpreted carefully and 
in combination with the clinical interview. The mainstay technique is polysomnog-
raphy (PSG): the simultaneous recording of multiple signals to measure both sleep 
itself and associated physiological parameters such as breathing. Additional audio-
visual recording can be very useful, especially for diagnosing nocturnal movement 
disorders, such as REM sleep behavior disorder. Excessive daytime sleepiness can 
be objectified using the Multiple Sleep Latency Test (MSLT). Poryazova et al. found a 
significant correlation between ESS scores >10 (indicating excessive daytime sleepi-
ness) and short mean sleep latency (≤5 min) as measured with the MSLT.35 Although 
in daily practice the clinical interview and additional questionnaires are often suffi-
cient to diagnose excessive daytime sleepiness, an MSLT can be considered when 
3332
Recognition and diagnosis of sleep disorders Chapter 2.1
2.1
Main sleep symptom Etiological category Diagnostic strategy
da
yt
im
e
Excessive 
Daytime 
Sleepiness
Disturbed nocturnal sleep 
(see nighttime)
Medication side- effect Clinical history, dedicated questionnaires (e.g. 
ESS), lower dose or change to different drug
Primary 
hypersomnia
Clinical history (exclusion of other causes), 
dedicated questionnaires (e.g. ESS), MSLT
ni
gh
t-
tim
e
Nocturnal 
Motor 
Symptoms
Nocturnal “off”: tremor, 
rigidity, akinesia, dystonia
Clinical history, when in doubt: video-
polysomnography
Dyskinesias Clinical history
Restless Legs Syndrome Clinical criteria, laboratory investigations 
(e.g. ferritin levels) 
Periodic Limb Movement 
Disorder
Polysomnography 
(interpretation by sleep specialist)
REM Sleep Behavior 
Disorder
Clinical history, video-polysomnography
Sleep 
Related 
Breathing 
Disorders
Sleep apnea syndromes 
(obstructive and/or central)
Clinical history, clinical examination, 
pulmonological evaluation, polygraphy/ 
polysomnograpy
Nocturnal stridor Clinical history, polysomnography with 
synchronous audio recording, consider
laryngoscopy
Other 
causes of 
insomnia
Depression, anxiety Clinical history, diagnostic questionnaires,
assessment by psychiatrist
Nightmares, hallucinations, 
psychosis
Clinical history, assessment by psychiatrist
Cognitive decline and 
dementia
Neuropsychological tests, check underlying 
treatable causes
Nocturia Clinical history, physical examination, 
urological evaluation
Nocturnal pain Clinical history, screen for comorbidity, 
physical examination 
Medication side-effects Clinical history, lowering dose or change 
to different drug
Primary insomnia Clinical history, exclusion of other causes
yes
In darker blue: typical indications for consultation with a sleep medicine specialist ESS: 
Epworth Sleepiness Scale; MSLT: Multiple Sleep Latency Test
Table 3. Diagnostic outline for sleep disorders in PD Figure 1.  Diagnostic flowchart for the assessment of sleep disorders in PD
Sleep complaint
Disturbed 
nocturnal 
sleep?
 · EDS as  
medication 
side-effect
 · Primary  
hypersomnia
 · Nocturnal ‘off’
 · Dyskinesias
 · RLS
 · PLMD
 · REM Sleep  
Behavior  
Disorder
 · Obstructive 
sleep apnea
 · Central sleep 
apnea
 · Nocturnal  
stridor
 · Depression, anxiety
 · Nightmares,  
hallucinations
 · Cognitive decline 
 · Nocturia
 · Nocturnal pain
 · Medication side-effect
 · Primary insomnia
yes
no
no
also consider
Nocturnal 
motor 
symptoms?
yes
no
yes
yes
also consider
No primary 
sleep disorder
Excessive 
daytime 
sleepiness?
Disturbed 
nocturnal 
sleep?
Sleep 
related 
breathing 
disorders?
nono
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tem. Thus, Fronczek et al. found a significant decrease in the number of hypocretin 
neurons and a lower hypocretin-1 concentration in ventricular CSF in post-mortem 
material.43 In the same issue of Brain, Thannickal et al. also described a decrease 
in hypocretin neurons, which correlated with disease stage.44 Unfortunately, these 
pathological findings do not translate into a clinically useful test: one study reported 
low hypocretin-1 levels in spinal CSF in only two out of eight PD patients with EDS, 
and other research groups found normal spinal CSF levels.35,45-47
Nocturnal motor symptoms
Nocturnal motor symptoms are an important cause of sleep disturbances in PD, 
and include nocturnal “off” symptoms and dyskinesias, in addition to primary sleep 
disorders such as restless legs syndrome (RLS), periodic limb movement disorder 
(PLMD) and REM sleep behavior disorder (RBD). 
Nocturnal “off”
Lees was the first to describe the phenomenon of nocturnal “off” in 1988, reporting 
that 65% of PD patients had difficulty turning around in bed.2 Nowadays it is widely 
appreciated that nocturnal “off” symptoms contribute to impaired mobility in bed, 
making it difficult to turn around or find a comfortable sleep position. Surprisingly, no 
one has studied the influence of impaired bed mobility on sleep quality and sleep 
structure. The diagnosis of sleep problems caused by nocturnal “off” is primarily 
based on the clinical interview. There is a major need for objective measurements to 
diagnose sleep disturbances caused by nocturnal “off” periods. Recently, Bossen-
broek et al. validated the use of a tri-axial accelerometer to measure the intensity of 
movements in addition to body position during sleep.48 This seems to be a promis-
ing new way to objectively measure nocturnal “off” periods in PD, even in the home 
situation. 
Dyskinesias
Levodopa-induced dyskinesias are sometimes more intense in the evening, for ex-
ample due to a cumulative effect of repeated doses of long-acting dopaminergic 
agents. Biphasic dyskinesias can also be severe in the evening after patients have 
taken their final evening dose of medication. Patients may report that these dyski-
nesias hamper the onset of sleep, or disturb sleep when dyskinesias return during 
nighttime arousals.49 However, no formal data are available on the prevalence and 
influence of nocturnal dyskinesias on sleep in PD patients. 
Different sleep problems 
Excessive daytime sleepiness
Excessive daytime sleepiness versus “sleep attacks”
The most important characteristic of excessive daytime sleepiness (EDS) is the 
tendency to actually fall asleep during the day, usually accompanied by a “build-
ing” feeling of sleepiness. Prevalence rates of EDS in PD range from 29% to almost 
60%.8,11,32,35-37 The term “sleep attacks” is often intermingled with EDS, but this is not 
justified. Sleep attacks are sudden, irresistible sleep episodes, often without warning 
signs. In the late 1990s, Frucht et al. described sleep attacks in PD patients while 
driving, after starting treatment with dopamine agonists.38 A large study from Can-
ada, including 638 consecutive PD patients, showed a prevalence of sleep attacks 
while driving of 3.8%.32 In only 0.7% of patients, sleep episodes occurred without 
any warnings signs. Sleep attacks can also occur during activities other than driving. 
Paus et al. reported sudden onset sleep while engaged in some form of activity (e.g. 
during a meal or phone call) in 580 of 2952 patients (19.6%).39 Körner et al. suggest-
ed even higher prevalence rates, with sudden sleep episodes in 42.5% of 6620 PD 
patients, but only in 19.2% during activities.40
Excessive daytime sleepiness versus fatigue
Although patients often describe EDS as “fatigue”, these represent two distinct 
symptoms. Fatigue is a feeling of tiredness and lack of energy, but does not result in 
unwanted sleep episodes.41 Moreover, EDS and fatigue are differentially associated 
with clinical features of PD.37 Specifically, fatigue is associated with higher scores on 
the motor part of the Unified Parkinson’s Disease Rating Scale (UPDRS III), higher 
Hoehn&Yahr stage and higher scores on a depression rating scale. Conversely, EDS 
is associated with disease duration and type of dopaminergic treatment; patients 
with non-ergot dopamine agonist had higher scores on the ESS.37
Causes of excessive daytime sleepiness
Many studies have described a correlation between EDS and the use of dopami-
nergic drugs.10-12 A recent study reported a dose-dependent effect of mean overall 
levodopa-equivalent dose and EDS, as measured with both ESS and MSLT. Impor-
tantly, this study analyzed the use of dopamine agonists, either alone or in combi-
nation with levodopa, but not levodopa alone.35 However, some authors found no 
relation between EDS and medication, and concluded that sleepiness was related 
directly to PD pathology.42 Recent studies focused on the possibility that EDS in PD 
may be related to damage to the hypothalamic sleep-regulating hypocretin sys-
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REM sleep behavior disorder
RBD is a parasomnia resulting from loss of normal atonia during REM sleep, leading 
to vigorous behavior with enactment of vivid and frightening dreams. The excessive 
motor activity may even result in injuries to the patient or bed partner.58 During the 
last decade RBD has shown to be a premarker of alpha synucleopathies such as 
PD.59,60 The prevalence of RBD in PD is estimated between 15-30%.58,61,62
Given the potential dangers and available treatment options, asking every PD pa-
tient and the bed partner for the presence of “dream enactment” is recommended 
(see Table 1). Eisensehr et al. found frequent misdiagnoses when RBD is established 
solely upon the clinical interview.63 As RBD also needs to be differentiated from other 
sleep disorders, such as obstructive sleep apnea, confusional arousals, nocturnal 
hallucinations and nocturnal frontal seizures, the threshold for doing a PSG should 
be low, even when the clinical interview is very typical.64
The gold standard for diagnosis remains a PSG with simultaneous audiovisual re-
cording. Video-PSG allows a confident diagnosis by showing an increase of tonic 
and phasic muscle activity in REM sleep, sometimes associated with actual motor 
behavior. The “SinBar group” – a collaboration between the sleep groups in Inns-
bruck and Barcelona – introduced an EMG montage protocol, and showed that si-
multaneous recording of the m. mentalis, m. flexor digitorumsuperficialis in the up-
Table 4.  Diagnostic criteria for RLS54Restless legs syndrome 
The dopaminergic system plays an important role in the pathophysiology of RLS, 
so it is to be expected that the prevalence of RLS is increased in PD. However, this 
relation between RLS and PD is not completely clear. Epidemiological studies yield-
ed conflicting results. Some authors reported increased RLS prevalence rates of 
up to 21% in Caucasian PD patients.50 In contrast, a recent study could not confirm 
this high prevalence, although the study population was on relatively high levodopa 
doses, which may have influenced the outcomes.51
RLS and PD may share a therapeutic response to dopaminergic drugs, but other 
characteristics point to a differential or additional effect of PD pathology. Compared 
to idiopathic RLS patients, PD patients with RLS have a higher age of onset and less 
often a positive family history of RLS.50 In addition, studies using transcranial sonog-
raphy found a significantly decreased echogenicity of the substantia nigra in patients 
with idiopathic RLS compared to PD patients with or without RLS, and healthy con-
trols.52,53
Regardless of the exact prevalence, it remains important to be vigilant for the pres-
ence of restless legs in PD, because RLS has a negative influence on quality of life, 
while the symptoms can often be treated satisfactorily. Note that specific PD symp-
toms – such as akathisia – may obscure the diagnosis of RLS. Therefore, it is import-
ant to adhere to the diagnostic guidelines which emphasize the presence of all four 
core features (Table 4).54 Secondary RLS should be excluded using appropriate in-
vestigations. In the general population, iron deficiency is the most common cause of 
secondary RLS, and one study confirmed this association in PD patients with RLS.30 
Ferritin levels are the best marker for iron deficiency.30,54
Periodic limb movement disorder
Periodic limb movement disorder (PLMD) often co-occurs with RLS, but is a dis-
tinct disorder. Literature on the presence of PLMD in PD is scarce. Arnulf et al. found 
PLMD in 15% of a PD patient cohort,42 which is clearly higher than population esti-
mates (which range around 8%).55 Another study found more periodic limb move-
ments in patients with PD compared to controls, but also compared to patients with 
MSA.56 It is often assumed that periodic limb movements result in arousals from 
sleep, resulting in daytime symptoms. However, Arnulf et al. found no association 
between the presence of PLMD and daytime sleepiness.42 Indeed, periodic limb 
movements are often asymptomatic, making it difficult to assess their clinical sig-
nificance.57
Required criteria
 · Uncomfortable and unpleasant sensations in the extremities (prickling, stinging, 
itching, “like crawling ants”, sometimes described as pain), with an urge to move 
 · The sensations begin or worsen during inactivity
 · The sensations and/or urge to move are partially or totally relieved by movement
 · The sensations and/or urge to move display a circadian pattern: worse in the 
evening or night compared than the early morning; or only occurring in the 
evening or night 
Supportive features of RLS
 · Positive family history
 · Clear beneficial response to dopaminergics
 · Presence of periodic limb movements during sleep
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Established risk factors for OSAS – such as increased neck circumference and ret-
rognathia – obviously also apply to PD patients. However, there is no correlation be-
tween the presence of OSAS and snoring, sleepiness or elevated body mass index 
in PD.71
Although OSAS is not more prevalent in PD patients compared to controls, the prev-
alence rate is still 15-30%, so clinicians should remain vigilant for its presence.70,71 
The diagnostic yield of PSG versus limited respiratory polygraphy to detect sleep 
apnea in PD has not been studied. Given the complexity of sleep disturbances in 
PD with a high frequency of combined disorders, we advocate the use of full PSG 
whenever a sleep registration is deemed necessary.
Nocturnal stridor 
Nocturnal stridor is a specific sleep-related breathing disorder, that is mainly associ-
ated with multiple system atrophy.72 Its presence has therefore differential diagnostic 
value in the workup of an extrapyramidal disorder. In addition, stridor is associated 
with a decreased life-expectancy.73 Stridor can be recognized clinically as an in-
spiratory vocalization with a strained, harsh and high-pitched (260-330 Hz) sound 
during sleep. To formally diagnose nocturnal stridor, a PSG with audiovisual moni-
toring should be performed.
Other causes of insomnia
When nocturnal motor symptoms and sleep-related breathing disorders are 
excluded, several other causes of disturbed nighttime sleep remain. Together, these 
may jointly be referred to as “insomnia”. Up to 60% of PD patients complain about 
insomnia, especially sleep fragmentation and early morning awakenings.4 Insomnia 
can take several different forms, manifesting as difficulty with initiating sleep, 
maintaining sleep, early-morning awakenings, or a combination of these. However, 
the diagnosis “insomnia” should be used with caution. “Insomnia” can have widely 
varying causes, and the generic term does not discriminate between them. In Figure 
1, these causes of problems with sleep initiation or maintenance are listed.
per limbs and m. extensor digitorum brevis in the lower limbs provides the highest 
rate of phasic EMG activity during REM sleep in patients with RBD.65 More recent 
work evaluated the diagnostic performance of this EMG montage, showing a sen-
sitivity of 94.4%, specificity of 47.2% and a negative predictive value of 41.9%.66 Until 
recently, however, no formal cut-off values were available to determine when phasic 
or tonic EMG activity in REM sleep is “too high”. In 2010, Montplaisir et al. established 
the first set of such parameters for idiopathic RBD which can be used in a clinical or 
research set-up.67 In addition to EMG-based polysomnographic methods, a poly-
somnographic video-based scale is now available to rate the severity of RBD.68
In addition to its clinical relevance, RBD also sheds highly interesting new light onto 
the regulation of motor activity in PD. De Cock et al. found a restoration of normal 
motor control during nighttime movements in association with RBD. The majority 
of bed partners of PD patients with RBD (87%) observed an improvement in move-
ment quality during RBD episodes (faster, stronger, or smoother).69 Video-PSG 
studies indeed showed body movements during REM without obvious signs of par-
kinsonism during REM. The exact meaning of these observations remain unclear, 
but it was hypothesized that these movements are somehow generated in the mo-
tor cortex, thus bypassing the defective extrapyramidal systems.69
Sleep-related breathing disorders
Sleep-related breathing disorders are relatively common among the general pop-
ulation. They are important to diagnose, as they may not only result in unrefreshing 
sleep and daytime sleepiness, but also negatively influence the long-term cardio-
vascular risk profile. 
The most common forms of sleep-related breathing disorders are sleep apnea syn-
dromes, divided into two types: obstructive sleep apnea (OSAS) and central sleep 
apnea. OSAS is characterized by repetitive episodes of complete or partial upper 
airway obstruction that occur during sleep. Two recent studies show no increased 
risk of OSAS in PD patients.70,71 In fact, one study even found a lower prevalence (27% 
in PD, compared to 40% in controls referred for daytime sleepiness).70 The frequen-
cy of sleep apnea did not differ between unselected PD patients and patients who 
were referred for sleepiness. Differences in patient population as well as selection of 
controls may explain the different results across studies.
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Introduction
Sleep disorders are a frequent non-motor symptom in Parkinson’s disease (PD), 
with an estimated prevalence of more than 70%.1-4 Poor sleep quality has a profound 
impact on quality of life.5,6 Sleep can be disturbed by a variety of reasons, ranging from 
insomnia to specific primary sleep disorders such as REM sleep behavior disorder.3,4,7 
The mechanisms underlying these various sleep disorders are heterogeneous.8,9
Despite their high prevalence and clear influence on quality of life, sleep disorders 
may receive insufficient attention in clinical practice.10 Chaudhuri et al. studied the 
underreporting of non-motor symptoms in 242 PD patients.10 To assess which 
non-motor symptoms were present, patients completed the Non Motor Symptom 
Questionnaire (NMSQuest) prior to their consultation.11 After their visit, patients were 
asked if they had discussed the marked items on the NMSQuest during the consul-
tation. Daytime sleepiness, insomnia, vivid dreams, acting out dreams or restless 
legs were present in up to 50% of patients, but 36-52% of these symptoms were not 
discussed during the consultation.10
The reason for this remains unclear. From the doctors’ perspective, there may be 
insufficient knowledge regarding sleep disorders, or a lack of time during a routine 
consultation. However, there also seems to be underreporting from the patients’ 
side. This does not mean that sleep is unimportant to patients. In the general 
population, sleep disruption creates a high disease burden and influences quality of 
life.12-14 One explanation for the underreporting of sleep problems is that PD patients 
do not always recognize their sleep problems as a separate, treatable symptom, but 
merely regard it as a “normal” part of their disease.10 It is also possible that patients 
do not consider their sleep problems to be a part of their PD at all, leading patients to 
think that their sleep issues should be discussed with another physician rather than 
the movement disorder specialist. Finally, the clinical phenotype of PD is very broad, 
involving a whole gamut of different motor and non-motor symptoms. Deciding 
which symptoms to address during the limited consultation time is understandably 
difficult.10
In this study, we addressed several aspects of sleep disorders in PD from a patients’ 
perspective. We used a priority list to assess the relevance of sleep disorders in 
comparison to other symptoms and daily issues in PD. Furthermore, we determined 
whether relevance from the patients’ view correlated with abnormal scores on sleep 
questionnaires.
Abstract
Introduction
Despite their high prevalence and clinical impact, sleep disorders in Parkinson’s 
disease (PD) appear to receive insufficient attention in clinical practice. We 
compared the importance of sleep disorders relative to other symptoms and daily 
issues. Furthermore, we determined whether relevance as perceived by patients 
correlated with the subjective presence of sleep disruption scored with a rating scale.
Methods
We studied a cohort of 153 consecutive patients (95 men) who were referred 
for problems other than sleep to our referral center. Prior to their visit, patients 
ranked their individual top 5 clinical priorities (out of 23 items), indicating the most 
problematic domains for which they requested medical attention. Additionally, 
nocturnal sleep quality and excessive daytime sleepiness were assessed with 
validated questionnaires. 
Results
The top three important domains according to the patient were movement (79.9%), 
medication (73.2%) and physical condition (63.4%). Sleep was the 6th most frequently 
reported item, marked by 37.9% of the patients. Among the patients who scored 
sleep as a priority, 47 (81%) had a poor sleep quality (Pittsburgh Sleep Quality Index 
>5). Although excessive daytime sleepiness was present in almost 30% of patients, 
a minority of them put it on their priority list. 
Conclusion
A priority list can be used to prioritize patient-centered quality of life issues. Our 
results show that sleep is a clinical priority for about one third of patients. Surprisingly, 
excessive daytime sleepiness was usually not prioritized by patients during the 
consultation, underscoring the need to use ratings scales alongside with subjective 
priorities. 
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Sleep
To assess sleep quality we used the Pittsburgh Sleep Quality Index (PSQI).19 The 
PSQI is a validated questionnaire frequently used in PD.20,21 The questionnaire as-
sesses different aspects of sleep such as subjective sleep quality, sleep latency, 
sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medication 
and daytime dysfunction. Sub scores on these areas are then combined to yield 
a total score that can range from 0 to 21. Poor sleep quality is indicated by a total 
PSQI higher than 5. Daytime sleepiness was assessed using the Epworth Sleepi-
ness Scale (ESS).22 The ESS is an easy to use questionnaire in which patients have to 
indicate the possibility to fall asleep in eight different situations. The ESS ranges from 
0-24 and a score of >10 indicates excessive daytime sleepiness (EDS). 
Data analysis
All statistical analysis was done using SPSS for Windows version 18. To compare the 
importance of sleep to other problem areas in PD, the number of times an item was 
marked on the patients’ priority list was counted and the results were ranked. In ad-
dition, the cohort was divided into patients who prioritized sleep and those who did 
not. To indicate if poor sleep quality and EDS are a reason to mark sleep as a priority, 
the presence of these problems was compared between both groups. Significance 
of comparison was calculated using t-test and chi-square test depending on the 
variable. Missing values were <5%, therefore all percentages are presented as valid 
percentages. All data are shown as mean±SD or N (%).
Results
Clinical characteristics
A total of 153 consecutive patients with PD were included (62.1% men). The clinical 
characteristics and mean scores on the PSQI and ESS are described in Table 1. Pa-
tients had an intermediate disease stage (majority at H&Y stage 2). There was a wide 
variety in use of levodopa and dopamine agonists. The LED ranged from 0-1300 
mg/day, with a mean LED of 468.4±336.5 mg/day. 
Priority of problem areas
In 80 patients, more than five items were scored on the priority list. We decided 
to include all marked items in the ranking analysis, because re-analysis excluding 
these patients resulted in only minor shifts in the final ranking. The top three import-
ant domains that needed clinical attention according to the patient were movement 
Patients and methods
Setting and study population
For this study, consecutive patients were included who visited the Parkinson Centre 
Nijmegen (ParC), a tertiary referral centre. ParC can be consulted by local neurol-
ogists to assess specific diagnostic and treatment difficulties in patients with par-
kinsonian disorders. Because the prevalence and characteristics of sleep disorders 
vary between the different forms of parkinsonism, we here focused on patients with 
idiopathic PD. This diagnosis was made by experienced movement disorder spe-
cialists and based on the UK Brain bank criteria.15 At our center, a comprehensive 
multidisciplinary team is available, including movement disorder specialists, physio-
therapists, occupational therapists, and speech-language therapists.16 Prior to their 
visit, patients completed questionnaires concerning all possible problem areas in 
PD, such as adequacy of treatment, movement, speech and sleep. At the end, pa-
tients were asked to indicate which symptoms and daily limitations particularly ne-
cessitated clinical attention, by composing a top 5 list of clinical priorities. The study 
was approved by the medical ethics committee of the Radboud University Medical 
Centre. All patients who were approached agreed in the use of their data for scientific 
purposes and gave informed consent for the study.
Clinical characteristics
Demographic variables were recorded, including disease duration. Disease stage 
was rated using the Hoehn&Yahr (H&Y) staging system.17 Dopaminergic treatment 
was quantified by calculating the Levodopa Equivalent Dose (LED) in mg/day.18
Priority list
To tailor the clinical visit, patients were asked to draft a priority list of their own most 
problematic areas they particularly requested attention during the clinical interview 
and assessments. To indicate their priorities, patients could choose from a list of 
23 items concerning all possible problem areas: living situation, medication advise, 
daily schedule, information on brain surgery, physical condition, memory, mood, 
behavior, sleep, autonomic dysfunction, drooling, speech, chewing and swallow-
ing, nutrition, movement, transport, medical devices, self care, household activities, 
leisure activities, employment, social contacts and sexuality. Some of these issues, 
such as autonomic dysfunction, were further explained in the questionnaires and 
accompanied by examples. Patients were asked to score a maximum of five out of 
these 23 items.
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(79.9%), medication (73.2%) and physical condition (63.4%). About a third of patients 
(37.9%) prioritized sleep as an item they wanted to discuss during their visit (Table 
2). Sleep was the 6th item on the list of 23 potential items. Among the non-motor 
symptoms, only memory problems scored slightly higher (66 patients, 43.1%). Clin-
ical PD characteristics did not differ between patients who put sleep on their priority 
list and those who did not (Table 1).
Prioritization in relation to nocturnal sleep quality
The mean score on the PSQI was 6.9±3.7. Poor sleep quality (PSQI >5) was pres-
ent in 60.8% of patients. Patients who prioritized sleep had significantly worse sleep 
quality (PSQI 9.3±3.8 vs. 5.5±2.8, p<0.001, Table 1). Analyses of the PSQI scores 
suggested that this difference was mainly determined by subjective sleep quality, 
estimated sleep latency and habitual sleep efficiency (Table 1). Among patients who 
prioritized sleep as a problem, 81.0% actually had poor sleep quality (Table 3). Strik-
ingly, among patients with poor sleep quality (PSQI >5), only 50.5% of patients put 
sleep on their priority list. In the subgroup of patients with the most disturbed sleep 
(indicated by a PSQI score >10), the majority of patients did report this as a problem 
(82.1%). 
Prioritization in relation to excessive daytime sleepiness
The mean score on the ESS was 8.0±5.2. EDS (ESS >10) was present in 29.7% of pa-
tients. Interestingly, patients who prioritized sleep had exactly the same ESS scores 
as patients who did not (8.0±5.2, Table 1). Among all patients who put sleep on their 
priority list, 18 (32.1%) had EDS (Table 3). Conversely, among patients with EDS, only 
40.9% prioritized sleep as an item to discuss during consultation. Even in patients 
with more severe EDS (ESS>12), only 35.5% reported sleep as a priority. 
Prioritization in relation to overall sleep problems
To examine whether sleep problems in general (either nocturnal sleep problems, 
EDS, or both) were a reason to seek medical attention, we combined the PSQI and 
ESS results. This analysis showed that the vast majority (91.1%) of patients who prior-
itized sleep indeed had some form of sleep disturbance (PSQI >5, ESS >10 or both). 
However, many significant sleep problems remained undeclared: 49% of patients 
with nocturnal and/or daytime sleep dysfunction did not put sleep on their priority 
list (Table 3).
Total Sleep 
prioritized
Sleep not 
prioritized
p
Total 153 58 95
Gender man 95 (62.1%) 32 (55.2%) 63 (66.3%) .168
Age (yr) 65.9±9.7 66.3±8.8 65.6±10.2 .679
Disease duration (yr) 7.7±5.7 7.9±6.7 7.5±5.0 .639
LED (mg/day) 468.4±336.5 467.6±286.8 468.9±365.0 .982
Hoehn 
& Yahr
1 8 (5.5%) 1 (1.7%) 7 (7.7%) .648
1.5 6 (4.1%) 2 (3.7%) 4 (4.4%)
2 74 (51.0%) 31 (57.4%) 43 (47.3%)
2.5 20 (13.8%) 6 (11.1%) 14 (15.4%)
3 29 (20.0%) 12 (22.2%) 17 (18.7%)
4 7 (4.8%) 2 (3.7%) 5 (5.5%)
5 1 (0.7%) - 1 (1.1%)
PSQI 6.9±3.7 9.3±3.8 5.5±2.8 <.001
 · PSQI sub scores 
 · Subjective sleep quality 1.1±0.8 1.5±0.8 0.79±0.5 <.001
 · Sleep latency 0.9±1.1 1.5±1.2 0.6±0.8 <.001
 · Sleep duration 0.9±0.9 1.4±1.0 0.6±0.8 .014
 · Habitual sleep efficiency 1.0±1.2 1.7±1.2 0.6±0.9 <.001
 · Sleep disturbance 1.5±0.6 1.6±0.5 1.4±0.6 .572
 · Use of sleep medication 0.5±1.0 0.6±1.1 0.5±1.0 .280
 · Daytimefunction 1.1±0.7 1.3±0.7 1.1±0.8 .713
ESS 8.0±5.2 8.0±5.2 8.0±5.2 .996
Table 1.  Clinical characteristics
Results are shown as mean ±SD or N (%).; LED = Levodopa Equivalent Dose, PSQI = Pittsburg 
Sleep Quality Index, ESS= Epworth Sleepiness Scale
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Table 2.  Priority of problem areas among 153 patients with Parkinson’s disease 
Results are shown as the number of patients who put the item on their priority list N (%)
Table 3  Sleep problems as a reason to prioritize sleep
PSQI = Pittsburgh Sleep Quality Index; ESS = Epworth Sleepiness Scale
Prioritized Prioritized
Movement 122 (79.7) Nutrition 36 (23.5)
Medication 112 (73.2) Information about brain surgery 33 (21.6)
Physical condition 97 (63.4) Behavior 32 (20.9)
Memory 66 (43.1) Chewing/swallowing 32 (20.9)
Speech 59 (38.6) Medical devices 32 (20.9)
Sleep 58 (37.9) Leisure activity 32 (20.9)
Autonomic dysfunction 56 (36.6) Self care 28 (18.3)
Mood 48 (31.4) Daily schedule 23 (15.0)
Sexuality 44 (28.8) Living situation 21 (13.7)
Drooling 43 (28.1) Employment 21 (13.7)
Transport 39 (25.5) Household activities 20 (13.1)
Social contacts 37 (24.2)
Sleep quality Sleep not prioritized Sleep prioritized Total
PSQI ≤ 5 49 11 60
PSQI > 5 46 47 93
95 58 153
Daytime sleepiness Sleep not prioritized Sleep prioritized Total
ESS ≤ 10 66 38 104
ESS > 10 26 18 44
92 56 148
Sleep problems Sleep not prioritized Sleep prioritized Total
No sleep problem 39 5 44
Sleep problem 53 51 104
92 56 148
Discussion
Sleep matters for many patients with PD. Our results show that sleep problems are 
an important issue among other symptoms and daily limitations in PD. Especially 
poor nighttime sleep quality is a reason to call for medical attention. Surprisingly, 
EDS was rarely a reason to address sleep during the consultation, despite the ap-
parent clinical impact. 
Sleep problems as a reason to prioritize sleep
As in previous studies, 70% of patients had a disturbed sleep.1-4 81% of patients who 
prioritized sleep as an item to discuss had poor sleep quality. Moreover, more than 
90% had either poor sleep quality, EDS, or both. This indicates that when a patient 
marks sleep on his priority list, there is indeed a sleep problem and further analysis 
is warranted. 
Remarkably, not all patients with sleep problems marked this on their priority list. 
One explanation is that patients do not recognize their sleep as being poor. They are 
not aware that their sleep disturbance is related to their PD, and possible treatment 
options exist.23 Another possible explanation is that, although sleep is disturbed, 
other issues are more important at the time of consultation. Therefore patients do 
rate it within the five most important issues to discuss. This theory is supported by 
the fact that patients with the poorest sleep quality (PSQI >10) did prioritize sleep. Es-
pecially EDS alone was no reason to prioritize sleep for the majority of patients. Next 
to the other explanations, this could also be caused by the fact that patients, wrongly, 
do not perceive their EDS as a sleep problem. Symptoms are present during the day 
and patients may not associate EDS with nighttime disturbances. Moreover, patients 
often consider EDS equivalent to fatigue, which is in fact a different symptom.24
Assessing problem areas from the patient perspective
In the last few years patient-centeredness has become increasingly important as 
determinant of good quality of care. Patients who receive more involvement in their 
care are more satisfied and more compliant.25 Issues that are important for a pa-
tients’ quality of life may well differ from those issues that are typically addressed 
by doctors, such as drug effectiveness.26 One way to assess the different aspects 
involved in a patients’ health-related quality of life is the use of quality of life rating 
scales, such as the Parkinson’s disease quality of life rating scale (PDQL).27 Com-
pleting and checking these questionnaires, however, can be time-consuming for 
both patient and physician. Moreover, although these scales give a good impres-
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Eighty patients marked more than the requested maximum of 5 items on their prior-
ity list. In PD, possible hyperactivity of the substantia nigra may put a “brake” on cog-
nitive responses and as a consequence lead to indecisiveness.31 It is possible that 
this mechanism causes PD patients to have difficulty prioritizing their complaints. 
This may be a disadvantage of our priority list, which includes a broad range of pos-
sible symptoms related to PD. However, we feel that such apalette of explicit choic-
es is necessary. Sleep disturbances and other (non-motor) symptoms are regularly 
unrecognized as a problem related to their disease by PD patients. The use of a list 
of specific problem areas may to some extent prevent underreporting of symptoms, 
which may occur when patients would be asked to make a list of problem areas by 
themselves.
Our results show that a priority list is a helpful tool in the detection of sleep disorders 
in PD patients. Whether a priority list can also be helpful in detecting other symp-
toms and problem areas in PD should be further investigated.
sion whether certain problems exist or not, they do not show whether such prob-
lems are relatively important for any specific patient. In clinical practice, a priority list 
can be used as a “patient-centered quality of life scale”. By providing information on 
the issues that are important for a patient, such a list can also be used to guide the 
clinical consultation, and provide more directed clinical attention. We show that the 
relevance from the patients’ view correlated with the actual presence and severity of 
sleep disruption.
A priority list was first used by Politis et al.28 They assessed 265 consecutive PD 
patients to study which problem areas were most troublesome from a patients’ per-
spective. In agreement with our data, sleep was in the top 10 of problem areas.28 
Furthermore, sleep was also one of the most important non-motor symptoms. In 
our results as well as those of Politis et al. motor symptoms, medication and physical 
condition still are very important subjects for total group of PD patients.28 For specific 
patients however, other items can have higher priority to discuss. Both priority lists 
again point out the importance of addressing non-motor symptoms in a consul-
tation. In their study Politis et al. compared the presence of symptoms in early (≤ 6 
years disease duration) and advanced (> 6 years) patients.28 As a post hoc analysis, 
we also made this comparison, but found no difference in the results of the ranking 
between both groups (data not shown). 
Study limits and future prospectives
Asking a PD patient to make a priority list of issues to discuss during the consulta-
tion seems a promising tool for patient-centered care and improvement of treat-
ment. Our results are a step in studying the usefulness of such a list, showing that 
it indeed can pick up the presence of nocturnal sleep problems. Although pa-
tient-centeredness leads to better compliance, this does not directly imply better 
care. Future studies should assess of the use of priority lists leads not only to a 
better detection of sleep problems, but to a more focused and higher quality treat-
ment as well. Such research may also take into account the possible interaction 
between problem areas in PD, such as the influence of detecting and treating mood 
problems on sleep quality. Our cohort consisted of a large group of consecutive PD 
patients who visited a tertiary center. This could have biased the population in terms 
of e.g. disease severity. However, the clinical characteristics of our study population 
did not differ from other clinical trials in PD.29,30 Whether our results also apply to a 
different population (e.g. PD patients in homecare or a general hospital) should be 
studied in the future.
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Introduction
One of the major features of Parkinson’s disease (PD) is hypokinesia, defined as 
abnormally diminished motor function or activity. Hypokinesia in PD can severely 
interfere with daytime activities.1 Hypokinesia can also be present during the night.2,3 
Nocturnal hypokinesia is most typically reported by patients as having difficulties 
changing body position in bed. Complaints about bed mobility are often raised by 
PD patients. The estimated prevalence of subjective difficulties with turning around 
in bed ranges from 45% to more than 80%.4-6 Objective assessment of nocturnal 
movements showed that compared to controls, PD patients had a reduced total 
amount of nocturnal movements in bed, and a longer duration of turning events at 
night.7
Nocturnal hypokinesia is likely one of the factors responsible for the high prevalence 
of sleep disturbances in PD.4,8 Surprisingly, the exact relationship between nocturnal 
hypokinesia and sleep quality is not known. Stack et al. studied recumbent turning 
strategies in 39 PD patients, seven of whom were completely unable to turn in 
bed.5 Sleep initiation and maintenance were comparable between these two 
groups. However, turning difficulties were not graded. Gjerstad and al. showed that 
problems turning around in bed increased with duration of PD over a study period 
of eight years.6 Severity or prevalence of insomnia complaints did not increase, 
but no correlations were made between insomnia and nocturnal hypokinesia. Van 
Hilten et al. found that PD patients had a higher frequency of nocturnal hypokinesia 
compared to control subjects who had sleep maintenance problems.9 However, 
this study found no difference in nocturnal hypokinesia between PD patients 
and controls with sleep initiation problems, so further work remains needed to 
understand this issue.9
To date, nothing is known about the possible association between sleep disruption 
and problems turning around in bed within a group of PD patients. We therefore 
studied a large cohort of patients with PD, looking specifically at the relation between 
sleep quality on the one hand, and the presence and frequency of nocturnal hypo-
kinesia on the other. 
Abstract
Introduction 
In clinical practice problems turning around in bed are considered to negatively 
influence sleep in parkinson’s disease (PD), however this has not been studied. Here 
we studied the influence of nocturnal hypokinesia within a group of patients with PD.
Methods
Clinical and demographic data were obtained. Nocturnal hypokinesia was 
assessed using question 35 of the Parkinson’s Disease Quality of Life Questionnaire. 
The presence was rated on a 5-point Likert scale, ranging from 1=“all of the time” 
to 5=“never”. The Pittsburgh Sleep Quality Index (PSQI) was used to quantify sleep 
quality, higher scores indicating poorer sleep quality. 
Results
Out of 240 patients, 135 had difficulties turning around in bed. PSQI scores were 
significantly higher in patients with nocturnal hypokinesia (mean±SD) (PSQI 7.7±4.1) 
compared to those without (PSQI 6.1±3.4, p=0.001). A regression model correcting 
for age, disease duration and Hoehn&Yahr stage showed a significant influence 
of nocturnal hypokinesia on sleep quality (R-squared = 0.042, standardized-beta 
= 0.163, p= 0.026). Finally, there was a linear relationship between frequency of 
nocturnal hypokinesia and sleep quality.
Conclusion
This is the first study that documents that nocturnal hypokinesia negatively affects 
sleep quality in PD. Nocturnal hypokinesia therefore merits therapeutic attention, 
including optimal night-time dopaminergic treatment and education about turning 
strategies in bed.
66 67
Subjective impaired bed mobilityChapter 3.1
3.1
Quality of life
The PDQL is a validated questionnaire assessing quality of life in PD.12 It contains 37 
items in four sub scales: Parkinson symptoms, systemic symptoms, emotional func-
tioning and social functioning. An overall score can be derived, with higher scores 
indicating better quality of life. The total score ranges from 37-185. 
Data analysis
All statistical analysis was done using SPSS for Windows version 18. Patients scoring 
1-3 on item 35 of the PDQL were considered to have clinically relevant nocturnal hy-
pokinesia. We then compared clinical variables and sleep quality between patients 
with and without nocturnal hypokinesia. For the total PDQL, we replaced the score on 
item 35 by the mean score in this item in all patients, as we used item 35 as the pri-
mary outcome to assess nocturnal hypokinesia. T- and chi-square tests were used 
depending on the variable, with the exception of H&Y stage, which was assessed 
using a Wilcoxon signed rank test. In addition, we constructed a multiple linear re-
gression model to study the effect of nocturnal hypokinesia on sleep quality, in order 
to correct for confounding variables. Finally, the relation between PSQI scores and 
frequency rating of nocturnal hypokinesia was tested, using a linear regression mod-
el with trend analysis. Data are shown as mean±SD or N(%), unless otherwise stated. 
Results
Clinical characteristics and prevalence of nocturnal hypokinesia
In total, 240 PD patients were included (Table 1). Nocturnal hypokinesia was present 
in 135 patients (56.3%) during the last 3 months. Table 1 compares the clinical char-
acteristics between patients with and without nocturnal hypokinesia. Patients with 
difficulty turning around in bed were older, had a longer disease duration and more 
advanced disease, and used more dopaminergic treatment. 
Sleep quality
As expected, there was a high prevalence of poor sleep in the whole PD population, 
with almost 60% of patients having a PSQI >5. However, the prevalence of poor sleep 
was even higher in patients with nocturnal hypokinesia, as reflected by significantly 
higher mean PSQI scores (Table 1). 
Linear regression analysis confirmed the influence of nocturnal hypokinesia on sleep 
quality (R-squared = 0.042, standardized-beta = 0.204, p=0.002). We corrected the 
Patients and methods
Setting and study population
The Parkinson Center Nijmegen (ParC) serves as a tertiary university referral cen-
ter. Because of excellent collaboration with the surrounding hospitals, this center 
receives many referrals by local neurologists, including the entire spectrum of PD 
(ranging from de novo patients to complicated late-stage patients). For this study, 
we evaluated all consecutive PD patients who visited ParC in the year 2008.
Clinical characteristics
Demographic variables were recorded, including disease duration. Disease stage 
was rated using the Hoehn&Yahr staging system.10 UPDRS motor scores were not 
included in the analysis, because UPDRS rating was not a part of the routine assess-
ment in this clinical setting. Dopaminergic treatment was quantified by calculating 
the Levodopa Equivalent Dose in mg/day.11
Nocturnal hypokinesia
Nocturnal hypokinesia was rated using the patients’ ability to turn around in the bed, 
which is the most prominent clinical expression, which can also be rated easily by 
the patient. We therefore used question 35 of the Parkinson’s Disease Quality of 
Life Questionnaire (PDQL) which rates nocturnal hypokinesia as turning difficulties 
in bed.12 Patients have to rate the question: “How often in the last 3 months did you 
have trouble with difficulties turning around in bed?” on a 5-point Likert scale, rang-
ing from 1=“all of the time” to 5=“never”.
 
Sleep quality 
To asses nocturnal sleep quality, we used the Pittsburgh Sleep Quality Index 
(PSQI),13 a validated questionnaire which is frequently used in PD.14-16 The ques-
tionnaire assesses different aspects of nocturnal sleep, including sleep latency, 
duration and efficiency, subjective sleep quality and use of sleep medication. Sub 
scores are combined to yield a total score that can range from 0 to 21. Higher scores 
indicate worse quality of sleep. PSQI scores can be compared between groups. In 
addition, the prevalence of “poor sleep quality” can be measured, indicated by a 
PSQI score > 5.13
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regression analysis for the clinical variables that significantly differed between the 
two groups (age, disease duration, H&Y stage and LED). In the corrected model, 
nocturnal hypokinesia still had a significant effect on PSQI total score (R-squared = 
0.066, standardized-beta = 0.163, p=0.026).
The relation between frequency of difficulties turning around in bed and sleep qual-
ity showed a linear trend (contrast estimate 1.9, p=0.001) (Figure 1). PSQI scores 
ranged from 5.7±3.6 in patients without nocturnal hypokinesia, to 8.2±4.7 in patients 
who always had difficulties turning.
Finally, we compared PSQI sub scores between patients with and without noctur-
nal hypokinesia. Patients with turning difficulties reported a worse subjective sleep 
quality, used more sleep medication, and had worse daytime functioning (Table 1). 
Quality of life
Overall quality of life was significantly better in patients without nocturnal hypoki-
nesia compared to patients with nocturnal hypokinesia (142.5±18.1 vs. 120.5±19.6, 
p < .001). Nocturnal hypokinesia also negatively influenced the individual sub items 
of the PDQL (Table 1).
Figure 1. Linear regression model shows a linear trend of mean PSQI scores 
  and frequency of nocturnal hypokinesia
PSQI = Pittsburgh Sleep Quality Index 
Table 1.  Clinical differences between patients with and without nocturnal 
  hypokinesia
Results are shown as mean±SD or N (%). LED = Levodopa Equivalent Dose. PSQI = Pittsburgh 
Sleep Quality Index. PDQL= Parkinson’s Disease Quality of Life Index
aWilcoxon W test *PSQI range 0-21
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hypokinesia p
N 240 135 (56.3%) 105 (43.8%)
Men 146 (60.8%) 68 (46.6%) 78 (53.4%) .272
Age (yr) 65.1±9.6 66.5±8.8 63.2±10.3 .008
Disease duration (yr) 7.7±5.5 9.1±5.7 5.8±4.8 <.001
Hoehn 1 16 (7.0%) 2 (1.6%) 14 (14.0%) <.001a
& Yahr 1.5 11 (4.8%) 3 (2.3%) 8 (8.0%)
2 107 (46.9%) 55 (43.0%) 52 (52.0%)
2.5 40 (17.5%) 26 (20.3%) 14 (14.0%)
3 44 (19.3%) 32 (25.0%) 12 (12.0%)
4 10 (4.4%) 10 (7.8%) - 
LED (mg/day) 471.7±382.0 585.7±402.9 317.0±284.2 <.001
Sleep quality
 · PSQI* 7.0±3.9 7.7±4.1 6.1±3.4 .001
 · PSQI > 5 141 (58.8%) 87 (64.4%) 54 (51.4%) .042
 · PSQI sub scores
 · Subjective sleep quality 1.13±0.80 1.27±0.83 0.96±0.73 .003
 · Sleep latency 0.86±1.06 0.90±1.09 0.80±1.02 .452
 · Sleep duration 0.96±0.96 1.04±1.05 0.87±0.83 .159
 · Habitual sleep efficiency 0.93±1.15 1.01±1.17 0.84±1.11 .275
 · Sleep disturbance 1.46±0.59 1.54±0.58 1.36±0.57 .018
 · Use of sleep medication 0.57±1.01 0.77±1.23 0.32±0.85 .001
 · Daytime function 1.17±0.74 1.29±0.77 1.02±0.68 .004
Quality of life
 · PDQL 130.3±22.0 120.5±19.6 142.5±18.1 <.001
 · PDQL sub scores
 · Parkinson symptoms 47.9±8.5 44.2±7.8 52.8±6.9 <.001
 · Systemic symptoms 23.7±5.0 21.8±4.5 26.2±4.4 <.001
 · Emotional functioning 32.9±6.2 31.1±6.2 35.4±5.3 <.001
 · Social functioning 25.4±5.8 23.3±5.3 28.2±4.9 <.001
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minergic treatment, so the possible influence of night-time doses of dopaminergic 
agents on nocturnal hypokinesia could not be specifically addressed. The influence 
of dopaminergics on sleep is complex however, and to disentangle the specific effect 
on nocturnal hypokinesia may require future study. There is an effect on other sleep 
disorders in PD such as restless legs syndrome. On the other hand dopaminergic 
agents can for example cause hallucinations which can negatively influence sleep.
This study was not without shortcomings. First, selection bias may have affected our 
results. However, our population seemed representative of the general, “average” 
PD population in the community, with respect to age, disease duration and disease 
stage. Moreover, the reasons for referral to our center were highly diverse, and did not 
focus specifically on sleep problems. Still, almost 60% of patients had a PSQI score of 
more than 5, indicating significant sleep disturbances. This prevalence is in agree-
ment with other (epidemiological) studies on sleep disorders in PD.4,8,17,18 Compared 
to middle-aged adults, the mean PSQI score of our population was high.19 Second, 
our results were based on subjective complaints of turning problems in bed. It will 
be very interesting to use more objective devices to quantify nocturnal hypokinesia 
in future studies, for example using actigraphy or pressure sensors. However, these 
devices have not been assessed for their ability to measure hypokinesia in PD, so 
formal validation studies are required first. A recent study showed promising re-
sults of a tri-axial accelerometer worn on the trunk, aiming to assess physical activity 
and body position during the night in healthy controls.20 Such techniques should be 
used in future research to quantify nocturnal movements in PD, and further objectify 
our results showing a negative influence of hypokinesia on sleep quality. In addition, 
future studies should attempt to include other factors influencing sleep quality, such 
as other nocturnal movement disorders like restless legs syndrome and REM sleep 
behavior disorder. However, our data makes clear that in future studies assessing the 
complicated interaction between sleep-influencing factors in PD, nocturnal hypoki-
nesia should be specifically taken into account.
Discussion
Although important for many PD patients, the subject of nocturnal hypokinesia and 
sleep problems has thus far received little attention.4-7 Here we show a clear det-
rimental influence of difficulties turning around in bed on the quality of nocturnal 
sleep. Our data suggest a direct link between hypokinesia and sleep disruption, as 
the results were not explained by other associated factors such as disease duration 
and stage. Furthermore, there was a relationship between the frequency of noctur-
nal hypokinesia and sleep quality. 
Previous studies mostly compared PD patients with controls, and assessed hypoki-
nesia and sleep quality separately. This limits the interpretation of these results, be-
cause nocturnal sleep disturbances in PD have a very heterogeneous pathophys-
iology. Our data point to an influence of turning difficulties on sleep quality per se, 
and highlight the importance of treating this symptomof PD. Although significant in 
several analyses, the main difference of 1.6 on the PSQI seems small. This is in part 
caused by the structure of the PSQI, where clinically relevant changes on a specific 
aspect of sleep (e.g. total sleep time) is mitigated in the overall score. However, as an 
example, a change of 1.6 in the total PSQI score can be caused by a reduction of total 
sleep time by two hours, which obviously is clinically significant.
Analysis of PSQI sub scores confirmed our main findings, showing subjectively 
worse sleep quality in patients with nocturnal hypokinesia. Furthermore, these pa-
tients used more sleep medication and experienced more daytime dysfunction in 
relation to poor sleep. In the PSQI, the need for medication to improve sleep is used 
as an indicator of bad sleep quality. Therefore, all medication patients take to im-
prove sleep is taken into account, without specifying the type of medication used.
Interestingly, sleep latency did not differ between patients with and without noc-
turnal hypokinesia. This offers a possible explanation for the findings by van Hilten 
et al., who showed that problems turning around in bed did not differ between PD 
patients and controls with sleep initiation problems, while patients with sleep main-
tenance problems did have greater turning difficulties at night.9 These results may 
be explained by greater severity of axial hypokinesia, not at the time when patients 
fall asleep, but which develops during the night, presumably because the action of 
most dopaminergic treatments is too short to cover the entire night. This finding 
suggests an indication for slow release preparations or continuous dopaminergic 
stimulation. We did not have information about administration times of the dopa-
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Chapter 3.2 Objective impaired bed mobility
Introduction
Sleep disorders are of considerable burden to patients with Parkinson’s disease 
(PD). Up to 90% of PD patients report some form of sleep problem.1-3 Sleep can be 
disrupted by a wide variety of causes, and often multiple sleep disorders are present, 
including REM sleep behavior disorder, restless legs syndrome or sleep disordered 
breathing. Among the most prevalent sleep-related complaints in PD are difficulties 
with sleep initiation or maintenance, commonly referred to as “insomnia”.4-6 How-
ever, insomnia itself can have several different causes. For example, early morning 
awakenings can be related to an underlying depression. Nocturia can result in fre-
quent awakenings throughout the night. Importantly, 45-80% of PD patients with 
insomnia report to have problems turning around in bed and finding a comfortable 
sleep position.2,5,7 As such, subjectively impaired bed mobility may be one of the 
most important reasons for the high prevalence of insomnia in PD patients.2,3,8
The precise mechanism behind subjectively impaired bed mobility in PD is not clear. 
The complaint is often referred to as “nocturnal hypokinesia”. In addition, pain and 
overall muscle weakness can hinder a patient finding a comfortable sleeping posi-
tion.9 Regardless of the mechanism, PD patients seem to have less body position 
changes during the night compared to the general population.10 However, it remains 
unclear whether there is a relation between complaints of impaired mobility, actual 
number of body position changes and sleep quality. Such a relation would have clin-
ical relevance, as decisions to start nocturnal dopaminergic therapy are often made 
based on a subjective complaint of impaired bed mobility. 
In this study we assessed the influence of subjectively impaired bed mobility on 
objective sleep quality in patients with PD. Nocturnal body movements and sleep 
parameters were compared between insomnia PD patients with and without sub-
jective complaints of difficulty turning around in bed. In addition these parameters 
were also compared between PD patients and controls with primary insomnia.
Abstract 
Background
Impaired bed mobility may be an important reason for the high prevalence of 
insomnia in Parkinson’s disease (PD). Here we assessed the influence of subjectively 
impaired bed mobility on both subjective and objective sleep parameters in 
insomnia PD patients with and without complaints of impaired bed mobility and 
controls with primary insomnia. 
Methods
We included 44 PD patients with sleep initiation or maintenance problems and 44 
control subjects with primary insomnia. Sleep questionnaires, polysomnographic 
sleep parameters, activity data and number of body position changes were 
compared between PD patients and controls, and also within the PD group between 
patients with and without subjective complaints of impaired bed mobility (PD+IBM 
vs. PD-IBM). 
Results
54.5% of PD patients reported having impaired bed mobility. In the PD+IBM group, 
the number of body position changes was significantly lower than in PD-IBM (0.4/h 
(0.0-1.8) vs. 1.4/h (0.0-4.6), p=.015). Sleep efficiency was lower in PD+IBM patients 
(63.5, 26.2-85.6) compared to PD-IBM patients (78.4, 54.8-92.6, p<.001). 
Conclusion
PD patients who report impaired bed mobility have fewer sleep-related body 
position changes (i.e. nocturnal hypokinesia) than PD patients without such 
complaints. Furthermore, objective sleep efficiency is significantly diminished in 
these patients. 
78 79
3.2
Chapter 3.2 Objective impaired bed mobility
In the PD patients we additionally administered two sleep scales specifically de-
signed for PD; the Parkinson”s Disease Sleep Scale (PDSS) and the SCOPA-sleep.15,16 
The PDSS is a visual analog scale addressing 15 items concerning sleep such as 
general sleep quality, daytime sleepiness and nocturnal movements. The scores on 
the separate items can be converted to a total score ranging from 0-150, with high-
er scores indicating better sleep quality.15 The SCOPA-sleep contains two sections, 
assessing nocturnal symptoms and daytime sleepiness respectively.16 In addition, 
there is a final single question rating overall sleep quality. 
Polysomnography
All patients underwent one night of supervised video-polysomnography (PSG), 
using a dedicated recording system (Schwarzer AHNS, PelviTec BV, Delft, The 
Netherlands), scored with BrainRT software (BrainlaB, OSG, Rumst, Belgium). PSG 
registration included electroencephalography, electromyography of m. submenta-
lis and both m. tibialis anterior, electrooculography, electrocardiography and a full 
respiratory montage. Sleep stages were scored using the AASM 2007 criteria.17 The 
main sleep outcomes were total sleep time (TST), sleep efficiency (SE), sleep la-
tency, percentage of time in a specific sleep stage and number of awakenings per 
hour of sleep. Body position and movements were recorded using a position sensor 
placed on the thorax. Body position changes were verified using the video signal. 
Afterwards, total number of body position changes was determined. Actual number 
of body positions changes per night are influenced by the total sleep time, therefore 
the number of body position changes per hour was calculated. The outcomes were 
divided in body position changes per hour of sleep, per hour awake and per hour 
of the total time in bed. A turn causing a short awakening of maximum 30 seconds, 
directly followed by sleep was defined as a turn during sleep. 
Actigraphy
All PD patients underwent a night of actigraphy simultaneously with the PSG. The 
activity watch (Actiwatch, Cambridge Neurotechnology Ltd, Cambridgeshire, United 
Kingdom) was worn on the least affected side. Activity data were synchronized with 
the sleep stages recorded by the PSG. For each patient the frequency of activity 
periods during sleep and wake was determined. Finally the duration of the activity 
period and the level of activity was calculated.
Data analysis
All statistical analyses were done using SPSS for Windows version 18. Scores on 
sleep questionnaires, PSG data and actigraphy were compared between PD pa-
Patients and methods
Setting and study population
All patients were recruited from the outpatient clinic of the Sleep Medicine Center 
Kempenhaeghe, the Netherlands, a tertiary center for patients with sleep disorders. 
At this center, PD patients are seen in a dedicated program with a consultation fol-
lowed by attended video-polysomnography that night. 
Over a 2-year period, we included 44 consecutive PD patients with a primary com-
plaint of sleep initiation or maintenance problems (insomnia). All patients were re-
ferred to our sleep center as part of their regular care. Only patients with idiopathic 
PD were included. As a control group, we included 44 patients with primary psycho-
physiological insomnia who received a nocturnal polysomnography as part of their 
clinical workup. Insomnia patients in whom a primary nocturnal sleep disorder (such 
as sleep disordered breathing) was found, were excluded. The study was performed 
according to the guidelines of the Medical Ethical Committees of The Netherlands. 
All patients gave informed consent.
Clinical characteristics
Using a semi-structured interview, PD patients were divided in those with a sub-
jective complaint of impaired bed mobility, and those without. Demographic and 
clinical characteristics were recorded, including disease duration. Disease stage was 
rated using the Hoehn&Yahr staging system during the “on” phase.11 Overall do-
paminergic treatment was quantified by calculating the Levodopa Equivalent Dose 
(LED) in mg/day.12 In addition, nocturnal dopaminergic treatment was estimated by 
the dopaminergic dose taken before going to bed in LED (LED-night). 
Sleep questionnaires
Subjective sleep quality was measured using the Pittsburg Sleep Quality Index 
(PSQI).13 The questionnaire assesses different aspects of nocturnal sleep, includ-
ing sleep latency, duration and efficiency, subjective sleep quality and use of sleep 
medication. Sub scores are combined to yield a total score that can range from 0 to 
21. Higher scores indicate worse quality of sleep. “Poor sleep quality” is defined as 
a PSQI score > 5.13 Daytime sleepiness was assessed using the Epworth Sleepiness 
Scale (ESS).14 The ESS is an easy to use questionnaire in which patients have to in-
dicate the possibility to fall asleep in eight different situations. The ESS ranges from 
0-24 and a score of >10 indicates excessive daytime sleepiness (EDS). 
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Table 1. Demographic and clinical characteristics of PD patients with and 
  without impaired bed mobility 
Results are shown as median(range) or N (%). ; IBM+ = with impaired bed mobility; IBM- = 
without impaired bed mobility.; LED = Levodopa Equivalent Dose; LED-night = LED of dose 
before sleep; OSAS = obstructive sleep apnea; RBD = REM sleep behavior disorder; RLS = 
restless legs syndrome; PLMD = periodic limb movement disorder.
tients with and without subjective complaints of impaired bed mobility. In addition, 
sleep outcomes and frequency of body position changes were compared between 
PD patients and a control group with primary insomnia. Finally, an exploratory anal-
ysis was performed on the relation between sleep quality and body position chang-
es in PD patients, comparing patients with small and large numbers of nocturnal 
body position changes. 
Data were not normally distributed according to Kolmororov-Smirnov testing. 
Therefore, statistical comparisons were performed using the independent-samples 
Mann-Whitney-U test. Data are shown as median (range) and N (%). All results were 
of two-tailed tests, significance level was set at p <.05. 
Results
PD patients with and without impaired bed mobility 
Clinical characteristics
Of the 44 PD patients with insomnia, 24 (54%) also complained of impaired bed mo-
bility with difficulties turning around or finding a comfortable sleep position. The 20 
other patients did not report such problems. The main type of insomnia in PD+IBM 
patients comprised of sleep maintenance problems, as present in 23 (95.8%) of the 
patients. Eight (33.3%) PD+IBM patients solely had sleep maintenance problems, 
2 (8.3%) sleep maintenance as well as initiation difficulties, 6 (25.0%) sleep main-
tenance problems and early morning awakenings, and 6 (25.0%) complained of 
all three types of insomnia. Within the PD-IBM group, sleep maintenance prob-
lems were also the most common type, present in 16 (80.0%) subjects. Four (20%) 
patients only had sleep maintenance problems, 3 (15%) both sleep initiation and 
maintenance difficulties, 7 (35%) sleep maintenance problems and early morning 
awakenings, and 2 (10%) all three forms of insomnia. Presence of sleep mainte-
nance problems was not significantly higher in PD+IBM compared to PD-IBM (Chi- 
squared 2.715, p = .099). Table 1 compares the demographic and disease char-
acteristics between PD patients with and without subjective impaired bed mobility 
(PD+IBM versus PD-IBM). With the exception of disease stage, PD parameters were 
worse in de PD+IBM group, with longer disease duration and higher doses of do-
paminergic medication during the day. Dopaminergic medication taken at bed time 
however was not higher. In the PD+IBM group, the prevalence of REM sleep behav-
ior disorders was higher. 
PD+IBM PD-IBM p
N 24 20
Men (%) 14 (58.3) 14 (70.0) .423
Age (yr) 62.5 (50.0-74.0) 60.0 (36.0-82.0) .402
Disease duration (yr) 7.0 (1.0-22.0) 2.5 (0.5-7.0) <.001
LED (mg/day) 1143.8 (593.8-2557.5) 655.0 (0.0-1854.0) .001
LED-night (mg/before sleep) 125.0 (93.8-250.0) 93.8 (62.5 -187.5) .125
Hoehn & Yahr .149
1 2 (8.3) 1 (5.0)
1.5 1 (4.2) 3 (15.0)
2 11 (45.8) 14 (70.0)
2.5 4 (16.7) 1 (5.0)
3 6 (25.0) 1 (5.0)
Other sleep diagnoses
 · OSAS (%) 4 (16.7) 7 (35.0) .162
 · RBD (%) 17 (70.8) 8 (40.0) .040
 · RLS (%) 7 (29.2) 3 (15.0) .264
 · PLMD (%) 8 (33.3) 4 (20.0) .323
 · Mean activity score 10.4±11.5 7.2±5.4 .231
Sleep parameters
There were no differences in subjective nocturnal sleep quality or daytime sleep-
iness between PD patients with and without complaints of impaired bed mobility 
(Table 2). When assessing the PDSS subdomains, PD+IBM patients rated higher 
on the sub score “ nocturnal motor symptoms”, which includes painful cramps, 
dystonia and tremor (Table 2). PSG analyses also revealed differences in objective 
sleep parameters. Total sleep time and sleep efficiency were significantly lower in 
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Table 2.  Subjective and objective sleep quality and body movements in PD 
  patients with and without impaired bed mobility
Results are shown as median(range) or N (%). 
PSQI = Pittsburgh Sleep Quality Index; ESS = Epworth Sleepiness Scale; PDSS= Parkinson’s 
Disease Sleep Scale; SCOPA-NS/DS= SCOPA-sleep night symptoms/daytime sleepiness 
TST = total sleep time. SE = sleep efficiency. N1 (N2, N3) = percentage in stage 1 (2,3) sleep. 
REM = percentage in REM sleep.
the PD+IBM group. This was also reflected by a higher number of awakenings and a 
larger percentage spent awake at night. Actigraphy showed no difference between 
activity periods, duration of periods and activity levels during sleep or wake between 
PD+IBM and PD-IBM (Table 2).
Body position
The distribution of static body positions was not different between PD+IBM and PD-
IBM groups. Bed mobility however was significantly diminished in PD+IBM, with a 
reduction of more than 70% of number of body position changes during sleep (Table 
2). Interestingly, the frequency of body turns during wake at night was not different 
between groups, although this would be the period during which patients would 
actually note their problems with bed mobility (Table 2). 
Table 2.  Continued
PD+IBM PD-IBM p
N 24 20
Sleep questionnaires
 · PSQI 13 (5-18) 10 (5-19) .364
 · PSQI>5 22 (95.7) 19 (95.0) .919
 · ESS 6 (0-22) 11.5 (4-18) .160
 · ESS>10 7 (30.4) 11 (55.0) .103
 · PDSS 77.0 (47.8-100.8) 84.3 (53.5 -116.3) .083
 · Overall sleep quality 3.2 (0.2-8.9) 3.1 (0.4-7.2) .821
 · Insomnia 8.7 (0.6-18.4) 10.2 (1.9-16.2) .184
 · Nocturnal restlessness 7.6 (1.8-16.2) 10.2 (0.6-19.4) .811
 · Nocturnal psychosis 14.2 (7.6-19.0) 15.3 (3.7-20.0) .914
 · Nocturia 10.1 (3.3-18.4) 10.2 (8.6-17.4) .744
 · Nocturnal motor symptoms 19.7 (9.6-33.7) 28.4 (9.5-34.9) .021
 · Sleep refreshment 2.1 (0.6-9.1) 2.6 (0.3-8.4) .930
 · Daytime dozing 7.3 (1.3-9.8) 7.4 (0.9-9.7) .865
 · SCOPA-NS 11.5 (3-15) 8 (3-15) .138
 · SCOPA-DS 4 (0-16) 8 (1-16) .171
PD+IBM PD-IBM p
Polysomnography
 · TST (min) 298.0 (103.0-419.0) 379.6 (243.0-530.0) .001
 · SE (%) 63.4 (26.2 -85.6) 78.4 (54.8-92.6) <.001
 · Sleep latency (min) 9.7 (2.2-45.6) 6.6 (1.3-41.6) .383
 · N1 (%) 11.5 (1.9-49.8) 11.3 (1.1-(29.1) .465
 · N2 (%) 59.1 (22.2-90.3) 54.9 (42.9-79.9) .925
 · N3 (%) 15.1 (0.0-72.4) 15.9 (0-33.3) .555
 · REM (%) 12.3 (0.0-34.2) 12.5 (2.0-31.4) .768
 · Wake (%) 33.5 (13.7-73.7) 20.5 (4.7-45.2) <.001
 · Awakenings/hour sleep 5.7 (3.2-32.0) 4.5 (2.0-9.7) .005
Actigraphy
 · Sleep
 · Frequency of activity  
periods/hour
1.6 (0.0-7.9) 1.4 (0.0-9.3) .604
 · Duration of activity 
periods (min)
2.3 (1.4-6.0) 2.2 (0.5-4.2) .780
 · Level of activity periods 406,0 (0.0-111801.9) 433.0 (0.0-22400.5) .950
 · Wake
 · Frequency of activity  
periods/hour
5.7 (2.7-17.2) 5.6 (0.0-25.3) .553
 · Duration of activity  
periods (min)
5.5 (2.3-22.2) 6.0 (2.2-13.2) .958
 · Level of activity periods 7882.5 (342.0-28646.3) 6969.7 (0.0-44077.7) .587
Body position changes
 · Turns/hour during sleep 0.4 (0.0-1.8) 1.4 (0.0-4.6) .015
 · Turns/hr during wake at night 6.2 (0.3-14.1) 7.0 (0.0-16.5) .172
 · Turns/hour during total night 6.6 (0.3-15.0) 8.1 (0.0-19.1) .099
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Table 3. Clinical characteristics of PD and insomnia controls
 
Results are shown as median (range) or N (%). 
Table 4.  Subjective and objective sleep quality and body movements in PD 
  patients versus insomnia controls.
Results are shown as median(range) or N (%).; PSQI = Pittsburgh Sleep Quality Index; ESS = 
Epworth Sleepiness Scale; TST = total sleep time. SE = sleep efficiency. N1 (N2, N3) = percent-
age in stage 1 (2,3) sleep. REM = percentage in REM sleep.
PD patients versus controls with primary insomnia
Clinical characteristics 
Table 3 shows the clinical characteristics of the PD patients compared to the in-
somnia controls. Patients with primary insomnia were significantly younger than the 
PD patients. However, for all outcome measures, correction for age using a linear 
regression model did not change the results. 
Sleep parameters
The scores on sleep questionnaires and the PSG data for both groups are repre-
sented in Table 4. In both groups, the insomnia complaint was confirmed by a PSQI 
score above threshold. Insomnia controls reported an even worse subjective sleep 
quality as assessed by the PSQI than PD patients. 
Excessive daytime sleepiness (ESS>10) however was more common in PD patients. 
Interestingly, PSG data revealed that PD patients had a significantly worse sleep ef-
ficiency and a shorter total sleep time than insomnia controls (Table 4). The per-
centage of time awake during the night was almost twice as high in PD patients. 
This difference was mainly caused by the PD+IBM subgroup. Comparing TST and 
SE between PD-IBM patients and controls showed no significant differences (TST: 
PD-IBM 379.6 (243.0-530.0) vs. controls 400.5 (195.0-519.0), p= .448; SE: PD-IBM 
78.4 (54.8-92.6) vs. controls 82.4 (4.8-98.8), p= .201).
Body position changes
Lying in bed, PD patients spent a larger percentage of time in a supine position than 
insomnia controls (PD 41%±30.4 vs. control 23.6% 17.3, p.046), the latter spending 
more time laying prone (PD 6.8%±13.6 vs. control 15.3±18.9, p=.026). Both groups 
displayed a wide range in the frequency of body position changes during the night, 
but although a difference was seen between turns per hour during the total night, 
this difference was only marginally significant. Furthermore, no difference was found 
between turns during sleep and during wake (Table 4).
Influence of turns on sleep efficiency and total sleep time
To further analyze the influence of turning in bed on sleep quality we divided the PD 
group in “frequent” (n=19) and “rare” (n=25) turners. The cut-off between these groups 
was set at the mean number of turns per hour sleep in the total group (i.e. 1.0 turns/
hour). PSG data did not differ between these groups, suggesting that the actual num-
ber of body position changes per se does not influence sleep quality (total sleep time: 
rare turners 311.9 min (103.0-439.0) vs. frequent turners 358.5 min (130.5-530.0), 
p =.112; sleep efficiency : rare turners 66.3% (26.2-60.0) vs. frequent turners 69.6% 
PD Controls p
N 44 44
Men (%) 28 (63.6) 25 (56.8) .513
Age (yr) 61.0 (36.0-82.0) 45.0 (21.0-64.0) <.001
PD Controls p
N 44 44
Sleep questionnaires
 · PSQI 11 (5-19) 14 (6-19) <.001
 · PSQI>5 (%) 41 (95.3) 43 (100.0) .152
 · ESS 10 (0-22) 4 (0-17) <.001
 · ESS>10 (%) 18 (41.9) 8 (18.6) .019
Polysomnography
 · TST (min) 332.5 (103.0-530.0) 400.5 (195.0-519.0) <.001
 · SE (%) 68.4 (26.2-92.6) 82.4 (4.8-98.8) <.001
 · Sleep latency (min) 8.5 (1.3-45.6) 12.0 (1.5-251.5) .094
 · N1 (%) 11.3 (1.1-49.8) 8.8 (2.2-28.7) .059
 · N2 (%) 57.1 (22.2-90.3) 57.1 (39.4-80.2) .716
 · N3 (%) 15.2 (0.0-72.4) 15.4 (0.0-39.0) .632
 · REM (%) 12.3 (0.0-34.2) 17.3 (1.5-33.4) .001
 · Wake (%) 30.0 (4.7-73.7) 16.2 (1.2-62.1) <.001
 · Awakenings/hour 5.5 (2.0-32.0) 3.9 (0.6-8.6) .001
Body position changes
 · Turns/hour during sleep 0.6 (0.0-4.6) 0.7 (0.0-6.6) .770
 · Turns/hour during wake at night 6.6 (0.0-16.5) 7.9 (2.0-47.6) .058
 · Turns/hour during total night 7.6 (0.0-19.1) 8.8 (2.0-47.6) .046
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Table 5.  Sleep parameters in “rare” and “frequent” turners with and without 
  impaired bed mobility 
Results are shown as median (range) or N (%). 
TST = total sleep time. SE = sleep efficiency. 
Discussion
In this study, we show that PD patients who complain of subjectively impaired bed 
mobility move less during sleep, and have a significantly diminished sleep efficiency 
and total sleep time compared to patients without complaints. However, there is a 
broad range in the frequency of body position changes, and even subjects with al-
most no shifts in body position do not necessarily have impaired sleep quality. No 
correlation was found between turns during sleep and sleep efficiency. Among both 
rare and frequent turners, subjective complaint of impaired bed mobility determined 
the actual sleep disruption. This suggests that the subjective complaint of impaired 
bed mobility rather than the actual number of body position changes is related to 
insomnia. 
Previous studies have suggested that impaired bed mobility negatively influences 
sleep quality.8,18 Van Hilten et al. compared PD patients with healthy controls, show-
ing that in a cohort with sleep maintenance problems, turning problems were more 
frequent in the PD group. This suggest that difficulty turning interferes with sleep.18 
However, these results could also be explained by a co-occurrence of both insomnia 
and impaired bed mobility in PD, without a causal relation. Recently we compared 
subjective sleep quality and impaired bed mobility within a large cohort of PD pa-
tients, showing that subjective sleep quality was significantly worse in those patients 
with impaired bed mobility.8 The results of the present study objectively confirm this 
(31.3-92.6), p=.413). These results were supported by the finding that no significant 
correlation was found between turns during sleep and sleep efficiency in PD+IBM, 
PD-IBM and insomnia controls (Figure 1). Apparently, the subjective complaint of 
impaired bed mobility is more likely to influence sleep quality, rather than the actual 
number of body position changes itself. Indeed, when patients with and without com-
plaints of impaired bed mobility were compared in both the rare and frequent turners, 
total sleep time and sleep efficiency were diminished in the PD+IBM group (Table 5).
Figure 1.  Correlation between turns during sleep and sleep efficiency in 
  PD+IBM, PD-IBM and controls
IBM+ IBM- p
Rare turners N 17 (65.4%) 9 (34.6%)
(<1.0 turn/hour) TST (min) 282.8 (103.0-419.0) 370.5 (296.0-439.0) .009
SE (%) 63.2 (26.2-85.6) 76.9 (66.1-86.2) .005
Frequent turners N 7 (38.9%) 11 (61.1%)
(≥1.0 turns/hour) TST (min) 329.0 (130.5-419.0) 380.0 (243.0-530.0) .077
SE (%) 66.7 (31.3-71.6) 79.8 (54.8-92.6) .018
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to move more during sleep. Our control group consisted of patients with primary 
insomnia, which could have resulted in a higher number of body position changes 
per hour in this group. The PD patients however also suffered from insomnia, which 
probably abolishes this problem. Nocturnal movements and activity during the 
night are most likely very different in each individual and may be influenced by a 
wide variety a variables such as age, the use of hypnotics and underlying disease. It 
is therefore difficult to determine what a normal frequency of body position changes 
during sleep means. One may hypothesize that PD patients should in fact turn more 
during sleep than controls, e.g. because of pain and/or rigidity. This would mean 
that the difference in turning events between PD patients and controls may in reality 
even be larger.
The precise mechanism of impaired bed mobility is not clear. Problems turning 
in bed are probably a part of the overall axial motor impairments in PD.11 Rigidity, 
hypokinesia as well as bradykinesia are considered to play a role. Steiger et al. 
found an association between difficulty turning in bed and both axial rigidity and 
whole body bradykinesia in 19 PD patients. After levodopa treatment the turning 
in bed improved as well as the axial rigidity and bradykinesia.9 This however is in 
contrast to the findings of Lakke et al. describing patients with turning difficulties 
when lying recumbent. Levodopa therapy improved rigidity and bradykinesia, but 
turning difficulties remained.22-24 Lakke et al. stated that these turning problems 
were probably caused by “axial apraxia” rather than rigidity or bradykinesia in these 
patients.6,12,22 Our results show that there is a group of patients with a small number 
of body position changes during the night, but without subjective complaints. To 
get more insight into the mechanism of impaired bed mobility this particular group 
should be further studied. It would for example be interesting to know whether 
impaired bed mobility is associated with a specific type of PD (eg. postural- instability 
gait difficulties vs. tremor dominant) or is associated with the degree of bradykinesia 
or rigidity during the day.
Our study is not without limitations. Fluctuations of movement can be present in 
PD during the day, but probably also during the night, and we have not taken this 
into account. Future studies may also include “off” state assessments, and other 
measures of motor fluctuations. Cognitive decline may influence sleep quality in 
itself, but also the reliability of the rating scales used. The clinical interview suggested 
only small memory problems in a minority of our patients, but we did not perform 
formal cognitive testing.
negative association of impaired bed mobility on sleep: total sleep time and sleep ef-
ficiency were both significantly worse in PD patients with subjectively impaired bed 
mobility compared to those without. Moreover, the impact of impaired bed mobility 
on sleep is underlined by the fact that no differences were present in total sleep time 
and sleep efficiency between PD-IBM patients and controls. Remarkably, the dif-
ferences in body position changes for the PD+IBM and PD-IBM were found during 
sleep, and not during wake. This is in contrast to what would be expected based on 
clinical findings. PD+IBM patients complain of having problems finding a comfort-
able sleeping position keeping them from falling asleep. Our results however show 
no difference during this awake period. Suggesting that the insomnia is influenced 
by the subjective feeling rather than the actual number of body position changes. 
Other studies report increased nocturnal activity levels in PD patients compared to 
controls.19,20 Possible explanations for this are sleep fragmentation leading to more 
wake or presence of specific nocturnal motor disorders such as REM sleep behavior 
disorder. Although our results show a significant increase in wake time in PD+IBM 
compared to PD-IBM we did not find differences between activity frequency, 
duration or level during sleep or wake between both groups. Our controls did not 
have actigraphy so a comparison between PD and controls could not be made.
A limited number of studies focused on actual nocturnal movements in PD. Laihinen 
et al. compared bed mobility in 9 PD patients and 11 neurological healthy controls, 
using a static charge sensitive bed to indicate the presence of possible turn-over 
events at night.10 Movements were distributed in duration classes of <5 sec, 5-10 
sec, 11-15 sec, >15 sec. The results showed that overall, PD patients had fewer 
movements compared to controls, and turning events were almost 20 sec shorter in 
PD patients.10 In our study we show that nocturnal body movements in PD patients 
with insomnia are also less frequent than body position changes in patients with 
primary insomnia, but differences were small. We did find that PD patients spent a 
longer period of time lying supine than controls, which is in agreement with recent 
findings of Valko et al..21
The role of body position changes during sleep is rarely addressed in research. 
The general opinion is that diminished activity during the night is associated with 
poorer sleep quality. However, our data show that this is not necessarily the case: no 
correlation was found between sleep efficiency and turns during sleep. Moreover, 
several patients with few body movements during sleep did not have low sleep 
efficiency. In addition in clinical practice, subjects with primary insomnia tended 
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Introduction
The diagnosis of Parkinson’s disease (PD) based on the UK Brain bank criteria de-
mands the presence of bradykinesia together with either muscle rigidity, rest tremor 
or postural instability.1 Pathological studies have demonstrated that by the time PD 
diagnosis is made, 40-60% of dopaminergic neurons in the substantia nigra have 
already degenerated.2 PD does not only affect motor performance, but also leads to 
an increased occurrence of non-motor symptoms such as sleep disorders, auto-
nomic dysfunction and alterations of mood. The onset of most of these symptoms 
antecedes the clinical PD diagnosis.3 Imaging studies have shown that parts of the 
substantia nigra are affected 3-7 years prior to clinical diagnosis.2,4-6 The start of the 
PD-specific neurodegenerative process may even be years to decades earlier than 
the characteristic motor symptoms which enable clinical diagnosis of PD. This pro-
dromal phase is associated with an increased probability to have non-motor signs 
or symptoms (e.g. hyposmia,7,8 REM sleep behavior disorder,9-11 depression,12 con-
stipation12,13), and/or slight motor symptoms (e.g. reduced arm swing, trunk instabil-
ity,14 stiffness and slowness not sufficient for the diagnosis of PD but increasing the 
likelihood for its future onset15-17), and/or imaging abnormalities (e.g. enlarged hy-
perechogenic substantia nigra18-20). However, the non-motor signs are not specific 
for PD as they are frequently present in the elderly population or co-occur with other 
diseases.21 Based on the limitation of the different markers it seems promising to 
combine risk markers and clinical symptoms to best predict a PD-related early neu-
rodegenerative process. A promising approach to identify individuals at high risk for 
PD might be the use of transcranial sonography (TCS). This ultrasound sign (SN+) is 
prominent in more than 90% of diagnosed PD patients.18,20 In the elderly population, 
persons with SN+ assessed by TCS have a 17 fold increased risk of future disease 
onset within 3 years and 20.6 fold increased risk after 5 years.22
Nocturnal movements are clearly altered in PD patients, on the one hand with in-
creased activity levels (e.g. due to rapid eye movement (REM) sleep behavior disor-
der (RBD) or being awake), and on the other hand a decreased frequency of noc-
turnal turns.23-25 These changes may also precede the diagnosis of PD and could 
therefore be interesting to study as an early PD marker. Based on these earlier find-
ings, we hypothesized that (i) PD patients show different nocturnal movement pat-
terns compared to healthy controls, and (ii) smaller but still detectable differences in 
nocturnal movements may occur already in non-PD individuals with a potential high 
risk for future development of the disease (HR-PD) and may thus have the potential 
to serve as prodromal markers of the disease.
Abstract
Introduction
There is a need for prodromal markers to diagnose Parkinson’s disease (PD) 
as early as possible. Knowing that most patients with overt PD have abnormal 
nocturnal movement patterns, we hypothesized that such changes might occur 
already in non-PD individuals with a potentially high risk for future development of 
the disease.
Methods
Eleven patients with early PD (Hoehn&Yahr stage ≤ 2.5), 13 healthy controls, and 
33 subjects with a high risk of developing PD (HR-PD) were investigated. HR-PD 
was defined by the occurrence of hyperechogenicity of the substantia nigra in 
combination with prodromal markers (e.g. slight motor signs, olfactory dysfunction). 
A tri-axial accelerometer was used to quantify nocturnal movements during two 
nights per study participant. Outcome measurements included mean acceleration, 
and qualitative axial movement parameters such as duration and speed.
Results
Mean acceleration of nocturnal movements was lower in PD patients compared 
to controls. Frequency and speed of axial movements did not differ between PD 
patients and controls, but mean size and duration were lower in PD. The HR-PD 
group did not significantly differ from the control group in any of the parameters 
analyzed. 
Conclusion 
Compared to controls, PD patients had an overall decreased mean acceleration, 
as well as smaller and shorter nocturnal axial movements. These changes did not 
occur in our potential HR-PD individuals, suggesting that relevant axial movement 
alterations during sleep have either not developed or cannot be detected by the 
means applied in this at risk cohort. 
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ration and efficiency, subjective sleep quality and use of sleep medication. “Poor 
sleep quality” is defined by a PSQI score of higher than 5. Presence or absence 
of RBD was assessed with the RBD screening questionnaire (RBDSQ).35 This scale 
asks for a subjects’ behavior while dreaming, including “dream enacting behavior” 
and other RBD-associated features. The total score ranges from 0-13 and a score 
of more than 4 indicates RBD. Presence of restless legs (RLS) was assessed using 
a questionnaire based on the four cardinal features of RLS.36 A positive answer to all 
four features indicates RLS. 
Nocturnal movement assessment
Two nocturnal movement assessments were performed with three orthogonal ac-
celerometers mounted at the back (Dynaport® device, McRoberts, Den Haag, Ned-
erland).37 The device has a local memory card for data storage. Data are collected at 
100 Hz and stored on a secure digital memory card. The tri-axial monitoring provides 
information on rotations in the longitudinal axis when lying in bed. Night rest is stated 
as an “in bed period” indicated by longer periods registered as lying. All subjects com-
pleted a sleep diary when using the accelerometer, including periods awake during 
the night. If any discrepancies occurred between sleep times as provided by the sleep 
diary and sleep time registered by the accelerometer, the registration by the acceler-
ometer was synchronized by the data reported by the patient. The accelerometer gives 
information on two different aspects of nocturnal movement. First, general aspects of 
all movements, such as mean acceleration and mean movement time. Second, the 
device depicts information of axial turns during the night. The characteristics of the 
axial turns include size, duration and speed. Table 1 shows the different outcome 
parameters in both categories and their descriptions and units. Furthermore, vari-
ation of size, duration and speed of the axial turns during the night were evaluated 
by calculating the coefficient of variation (standard deviation divided by the mean). 
Data analysis
The first study hypothesis (that PD patients have different movements compared to 
controls) was tested by comparing nocturnal movements between PD patients and 
controls. The second hypothesis (that HR-PD subjects already show slight chang-
es in the nocturnal axial movements) was proven by comparing HR-PD individuals 
to controls. As the quantification of the movement acceleration can be influenced 
by other variables such as age and motor performance (UPDRS-III), a regression 
model correcting for these variables was applied. Statistical analyses were done us-
ing SPSS for Windows version 18. According to the Kolmogorov-Smirnov test, data 
were not normally distributed. Therefore, inference statistics and correlation analy-
Methods
Population and study design
All participants were investigated in the frame of the PMPP study (Progression 
Markers in the Premotor Phase of Parkinson’s disease).14,26 This study comprises 
a population of 16 PD patients in early disease stages, 40 individuals supposed to 
be at high risk for PD (see below) and 14 controls with no risk marker for PD. The 
aims of the PMPP study are to define (bio-) markers or symptoms which indicate 
progression into the clinical PD stage, thus allowing an earlier diagnosis. Therefore, 
the PMPP study focuses particularly on the detection of biomarkers for PD and pro-
gression markers in the prodromal phase of PD in individuals selected under the 
presupposition to be at high risk for developing PD (HR-PD). Recruitment strategy 
as well as inclusion/exclusion criteria are presented in detail elsewhere.14,26 In brief, 
individuals defined as HR-PD had hyperechogenicity of the substantia nigra in addi-
tion to concomitant risk or prodromal markers of PD. These subjects had at least one 
symptom defined as either (a) or (b): (a) one PD cardinal motor sign assessed by the 
Unified Parkinson’s Disease Rating Scale (UPDRS-III) motor part, (b) two of the fol-
lowing prodromal/risk markers: prevalence of depression or history of depression, 
hyposmia, one-sided reduced arm swing, positive family history of PD.27-30 All con-
trols had normal echogenicity of the substantia nigra,31 no signs of acute psychiatric 
diseases and a negative family history of PD.30,31 PD patients were defined according 
the UK Brain Bank criteria and recruited from the outpatient clinic of the Depart-
ment of Neurodegenerative Diseases, Tübingen, Germany. Inclusion criteria for PD 
patients were: disease stages ≤ Hoehn&Yahr stage 2.5, age older than 50 years, 
no deep brain stimulation and no verified genetic mutation known to cause PD.32 
Patients were assessed while taking their optimized antiparkinson medication. The 
study was approved by the ethical committee of the Medical Faculty of the University 
of Tübingen, and all individuals provided written informed consent. The participants 
included in the current study had at least two nocturnal registrations of sleep with an 
ambulatory device (see below) during the study period.
Clinical assessment
All participants underwent a thorough clinical examination by neurologists experi-
enced in the field of neurodegenerative disorders. Motor performance was evaluat-
ed with the UPDRS motor score (UPDRS-III).27 Overall dopaminergic treatment was 
quantified by calculating the Levodopa Equivalent Dose (LED) in mg/day.33 Subjec-
tive sleep quality was measured using the Pittsburg Sleep Quality Index (PSQI).34 
The PSQI assesses different aspects of nocturnal sleep, including sleep latency, du-
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controls (UPDRS-III: 0 (0-7)) compared to both the HR-PD subjects (UPDRS-III: 4 
(0-12), p<0.001) and PD patients (UPDRS-III:18 (7-47), p < .001) (Table 2). Based 
on the sleep questionnaires, nocturnal sleep quality and presence of RBD and RLS 
were not different among PD and controls and HR-PD and controls (see table 2 for 
details). However, one person of the control group scored positive for the presence 
of RBD based on the RBDQ, in the HR-PD and PD group six individuals with RBD 
according to the scale were identified.
Nocturnal movements in PD patients and controls
With respect to general movement assessment, mean acceleration was lower in PD 
patients compared to controls (PD 0.05 g (0.04-0.08) vs. controls 0.08 g (0.05-0.11), 
p < .001). Regression analysis showed that mean acceleration was slightly affected 
by the motor performance (UPDRS-III, beta -.001, p = 0.017) and frequency of turns 
(frequency beta -.003, p = .006). Although, the frequency of axial turns did not signifi-
cantly differ between both groups, the distribution and quality of the axial turns varied 
between PD patients and controls. Total size of axial turns was smaller (PD 32.6° (17.5-
46.9) vs. controls 46.7° (22.66-73.9), p < .001) and duration of turns was shorter (PD 
5.7 s (4.07-8.8) vs. controls 7.0 s (5.6-10.2), p = .001) in PD patients. Table 3 gives an 
overview of this data. Variability of axial nocturnal movement performance did not sta-
tistically differ between the two study groups (p>0.162, see table 3 for details). 
Nocturnal movements in HR-PD and controls 
Table 4 shows that mean acceleration of individuals with HR-PD did not significantly 
differ from controls. Furthermore, no differences were found in the characteristics of 
axial turns between HR-PD and controls, indicating that nocturnal axial movements 
are not yet affected in subjects with a high risk of developing PD.
RBD and nocturnal movements
Although no difference in the prevalence of RBD (18.2% PD, 18.2% HR-PD, 7.7% con-
trols; p= .443) was statistically verified, it could not be ruled out that the presence of 
RBD symptoms modulated the movement profile during the night. Therefore, data 
were additionally analyzed after exclusion of 9 individuals with RBD (Table 5 and 6). 
The mean acceleration was significantly lower (PD 0.05 g (0.04-0.08) vs. controls 
0.08 g (0.05-0.11), p < .001). Furthermore size (PD: 34.5° (17.5-46.9) vs. controls 
45.2° (11.7-63.1), p = .001) and duration was still shorter (PD 5.8 s (4.1-8.8) vs. con-
trols 7.0 s (5.6-10.2), p = .002; Table 4) in PD patients compared to controls. Again, 
no differences were found between HR-PD patients and controls in any character-
istic of nocturnal axial movements (Table 6). 
sis was based on the independent-samples Mann-Whitney-U test and Spearman’s 
rank correlation coefficient. Data are shown as median (range) and N(%) of persons. 
All results are of two-tailed tests, significance level was set at p < .05. 
Table 1.  Quantitation of nocturnal ambulatory movement parameters
Results
Data of 11 PD patients, 13 controls and 33 HR-PD were analyzed. This yielded 22 
nocturnal registrations of PD patients, 26 of controls and 66 of HR-PD. Thus, data of 
13 subjects were not included into the data analysis due to technical problems (n=1 
HR-PD), poor data quality (n= 2 PD, n=6 HR-PD) or withdrawal from participation in 
this part of the study (n=3 PD, n=1 control). 
Clinical characteristics and sleep questionnaires
Median disease duration of PD patients was 4.0 years (2.0-10.0). With respect to 
the antiparkinson medication, the median LED was 447.50 mg/day (100.0-1240.00 
mg/day). One patient had a Hoehn&Yahr score of 1, nine of 2, and one of 2.5. As 
could be expected based on the inclusion criteria, UPDRS-III scores were lower in 
In bed period (min)
Total period (in minutes) that the device considers 
a subject being in bed during the night.
General movements
Movements are all periods during the in bed 
period in which any movement was detected.
Mean acceleration (g) 
Mean amount of acceleration during all periods 
of movement during the in bed period. 
Total acceleration time (%)
Percentage of time during the in bed period that 
a subject moves.
Axial movements
An axial movement is each movement which 
results in an axial position change of at least 10°.
Frequency (movements/h)
Number of axial movements per hour of the in 
bed period.
Size (°)
The angle of the change in position resulting 
from the axial movement.
Duration (s) Number of seconds the axial movement lasts.
Speed (°/s) Mean size per second of the axial movement.
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Association between nocturnal movements and sleep problems
A correlation analysis between the PSQI score and the quantitative movement pa-
rameters was performed in order to rule out global effects of poor sleep quality on 
the alterations in axial nocturnal movements seen in our PD patients. We found no 
significant correlation between the PSQI score and the calculated movement pa-
rameters (mean acceleration = -.155; frequency = .185; size = -.127; duration = -.197; 
speed = .133, p all > .05).
Table 3.  Movement parameters in PD and controls
Median (range), p scores based on independent samples Mann-Whitney U test
CV = coefficient of variation
Table 2.  Clinical variables of the three groups
Median (range), p scores based on independent samples Mann-Whitney U test; p1 = p control 
vs. high risk; p2 = p control vs. PD; UPDRS III = Unified Parkinson’s Disease Rating Scale Motor 
Symptoms, PSQI = Pittsburgh sleep quality index, ESS = Epworth Sleepiness Scale, RBDQ = 
REM Sleep Behavior Questionnaire, RLS = presence of restless legs syndrome based on the 
four cardinal symptoms
Controls High risk p1 PD p2
N patients 13 33 11
Men (%) 6 (46.2) 25 (75.8) .054 7 (63.6) .392
Age (yr) 64.0 (56.0-78.0) 63.0 (55.0-73.0) .557 65.0 (51.0-81.0) .691
UPDRS III 0 (0-7) 4 (0-12) .001 18 (7-47) <.001
Sleep questionnaires
 · PSQI 4 (0-9) 4 (0-15) .242 5 (1-11) .134
 · PSQI >5 (%) 2 (15.4) 13 (39.4) .118 5 (45.5) .106
 · RBDQ 1 (0-5) 2 (0-10) .189 2 (1-11) .252
 · RBDQ≥ 5 (%) 1 (7.7) 6 (18.2) .207 2 (18.2) .274
 · RLS (%) 0 (0.0) 1 (3.0) .526 1 (9.1) .267
PD Controls p
N participants 11 13
N registrations 22 26
In bed period (min) 399.1 (238.5-725.6) 458.7 (230.2-596.9) .185
Mean acceleration (g) 0.05 (0.04-0.08) 0.08 (0.05-0.11) <.001
Total acceleration time (%) 1.8 (0.5-13.4) 1.5 (0.7-4.2) .148
Total axial movements
 · Frequency (movements/h) 5.0 (0.7-17.8) 3.1 (1.2-8.4) .148
 · Size (°) 32.6 (17.5-46.9) 46.7 (22.7-73.9) <.001
 · Duration (s) 5.7 (4.1-8.8) 7.0 (5.6-10.2) .001
 · Speed (°/s) 6.8 (4.1-9.4) 7.4 (4.1-12.7) .203
Variability of movements
 · CV size 0.7 (0.5-1.1) 0.6 (0.4-0.9) .475
 · CV duration 0.6 (0.4-0.8) 0.52 (0.3-0.8) .162
 · CV speed 0.5 (0.3-1.1) 0.6 (0.4-0.9) .259
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Table 5. Movement parameters PD and control
Median (range), p scores based on independent samples Mann-Whitney U test
CV = coefficient of variation
Table 4.  Movement parameters in HR-PD and control
Median (range), p scores based on independent samples Mann-Whitney U test
CV = coefficient of variation
HR-PD Controls p
N participants 33 13
N registrations 66 26
In bed period (min) 458.9 (246.7-623.4) 458.7 (230.2-596.9) .927
Mean acceleration (g) 0.07 (0.05-0.12) 0.08 (0.05-0.11) .098
Total acceleration time (%) 1.4 (0.4-5.1) 1.5 (0.7-4.2) .351
Total axial movements
 · Frequency (movements/h) 3.0 (0.5-8.6) 3.1 (1.2-8.4) .703
 · Size (°) 51.2 (18.8-77.0) 46.7 (22.7-73.9) .052
 · Duration (s) 7.8 (3.4-15.6) 7.0 (5.6-10.2) .134
 · Speed (°/s) 7.5 (4.2-14.0) 7.4 (4.1-12.7) .640
Variability of movements
 · CV size 0.6 (0.0-1.2) 0.6 (0.4-0.9) .456
 · CV duration 0.5 (0.3-0.9) 0.5 (0.3-0.8) .278
 · CV speed 0.6 (0.4-1.3) 0.6 (0.4-0.9) .775
PD Controls p
N participants 9 12
N registrations 18 24
In bed time (min) 392.4 (238.5-513.3) 462.6 (230.2-596.9) .064
Mean acceleration (g) 0.05 (0.04-0.08) 0.08 (0.05-0.11) <.001
Total acceleration time (%) 1.8 (0.5-13.4) 1.6 (0.7-4.2) .213
Total axial movements
 · Frequency (movements/h) 4.6 (0.7-17.8) 2.9 (1.2-8.4) .374
 · Size (°) 34.5 (17.5-46.9) 45.2 (11.7-63.1) .001
 · Duration (s) 5.8 (4.1-8.8) 7.0 (5.6-10.2) .002
 · Speed (°/s) 6.8 (4.1-9.4) 7.1 (4.1-10.2) .550
Variability of movements
 · CV size 0.6 (0.5-1.0) 0.7 (0.4-0.9) .517
 · CV duration 0.5 (0.4-0.8) 0.6 (0.3-0.8) .731
 · CV speed 0.6 (0.3-1.1) 0.6 (0.4-0.9) .182
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Nocturnal movement alteration in overt PD
In our PD sample, we identified a decrease in mean acceleration during the night. 
Looking at the characteristics of the axial turns, PD patients made smaller turns, in 
shorter time periods. A lower frequency of turning-over events in bed in PD patients 
was reported by Laihinen and colleagues, however we could not support this.25 In 
contrast, elevated nocturnal activity level and an increased proportion of time with 
movement have been reported in PD as well.23,24 The latter findings are based on 
the quantification of an activity level. This elevated activity level might be influenced 
partly by movements occurring in prolonged periods in which patients are awake 
during the night. This might also be a problem in our results. Bedtime was mea-
sured as a longer period of lying, however this does not directly indicate a person is 
asleep. Using the sleep diaries of the patients, we narrowed this period based on the 
patients’ experience of being asleep. We believe this combination of factors gives 
a good comprehension of actual sleep, however future studies may overcome this 
issue by use of polysomnography. 
During the day, an increase of variation in (gait) movements has been described in 
both PD patients and in a genetically defined PD at risk cohort.38,39 Our data sug-
gests that the variability of axial movements is not altered during the night in PD pa-
tients. An explanation of this could be that PD related neurodegeneration mostly af-
fects voluntary day time movements rather than the involuntary movements during 
the night. However, further research is needed to verify this finding. 
In general, our data suggest that PD patients may attempt to turn, but are not able 
to reach the full size of movements. Although size and duration of movements were 
altered in the PD group, the speed level of movements was similar to that of healthy 
controls. From this finding one could speculate that PD-related axial motor dysfunc-
tion during the night influences the size of the movements rather than its speed. 
Nocturnal movement alteration in the prodromal stage of PD
There are currently several ongoing studies attempting to identify PD biomark-
ers, although further identification of these markers is necessary.21 To date, several 
non-motor and motor risk factors have been reported to increase the risk for later 
development of PD, especially presence of RBD.15,16,40 In our sample, frequency of 
RBD did not differ between the PD and HR-PD group, suggesting that frequency of 
RBD in our HR-PD cohort resembles that in PD. As we expected that RBD symp-
toms might affect the interpretation of our nocturnal axial movement data, analysis 
was replicated after exclusion of all subjects with signs of RBD. Our analysis revealed, 
Discussion
The aim of this study was to examine axial nocturnal movements in early PD stages 
and in the prodromal phase of PD, hypothesizing that PD patients might show dif-
ferent axial nocturnal movement patterns compared to healthy controls. Moreover, 
we speculated that these abnormalities might even be prominent in the prodro-
mal phase of PD and may thus have the potential to serve as preclinical markers of 
the disease. Our results suggest that mean acceleration, size and duration of axial 
movements are especially altered in the overt motor phase of PD, but not in our in-
dividuals suggested to be at high risk for the development of PD. 
Table 6.  Movement parameters in HR-PD and control
Median (range), p scores based on independent samples Mann-Whitney U test
CV = coefficient of variation
HR-PD Controls p
N participants 27 12
N registrations 54 24
In bed time (min) 460.1 (246.7-623.4) 462.6 (230.2-596.9) .983
Mean acceleration (g) 0.07 (0.05-0.10) 0.08 (0.05-0.11) .134
Total acceleration time (%) 1.5 (0.7-5.1) 1.6 (0.7-4.2) .527
Total axial movements
 · Frequency (movements/h) 3.1 (1.3-8.6) 2.9 (1.2-8.4) .845
 · Size (°) 50.4 (33.5-77.0) 45.2 (11.7-63.1) .021
 · Duration (s) 7.8 (4.4-15.6) 7.0 (5.6-10.2) .221
 · Speed (°/s) 7.5 (4.2-14.0) 7.1 (4.1-10.2) .488
Variability of movements
 · CV size 0.6 (0.4-1.2) 0.7 (0.5-0.9) .369
 · CV duration 0.5 (0.3-0.8) 0.6 (0.3-0.8) .127
 · CV speed 0.6 (0.4-1.3) 0.6 (0.4-0.9) .745
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independent from the presence of RBD, that frequency, speed, duration and inten-
sity of axial nocturnal movements were not altered in our HR-PD sample compared 
to controls. This leads to the conclusion that occurrence of RBD did not relevantly 
influence our general finding that axial nocturnal movements are different between 
PD and controls. 
As this is a cross-sectional study, we cannot “guarantee” that our HR-PD group in-
deed reflects a prodromal PD stage. However, we recently identified subtle signs of a 
balance deficit (i.e. increased variability of trunk acceleration) in this group, especially 
under challenging conditions.14,38 In our view, this argues in favor of the hypothesis 
that our HR-PD cohort indeed bears an increased risk for the development of PD. 
However, only longitudinal assessments will clarify how many persons of this group 
will develop PD in the near future. Imaging data monitoring abnormalities of the 
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will clarify how many persons of this group will develop PD in the future.
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Introduction
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia that 
occurs frequently in patients with Parkinson’s disease (PD), with an estimated prev-
alence of 30-60%.1-3 RBD is characterized by the enactment of dreams as a result of 
the loss of physiological atonia during REM sleep. Behaviors displayed include hit-
ting, kicking, shouting but also laughing. The associated dreams are often violent or 
frightening in origin, and sometimes patients harm themselves or their bed partners 
with their movements.1 Remarkably, the RBD-associated movements of PD patients 
are usually much faster, stronger and smoother than during the day, suggesting that 
the movements “bypass” the affected extrapyramidal systems.4
To make a diagnosis of RBD, the current 2nd edition of the International Classification 
of Sleep Disorders (ICSD-II) requires the combination of clinical features (either by 
history or on nocturnal video recordings) and the presence of REM sleep without 
atonia as an electromyographic (EMG) finding during sleep recordings (Table 1).5 The 
gold standard for the diagnosis of RBD therefore entails a clinical interview, preferably 
by a sleep medicine specialist, together with at least one night of polysomnography 
with audiovisual recordings (video-PSG). However, referring every PD patient with 
complaints of nocturnal restlessness to a sleep medicine center is time-consuming, 
expensive and may not always be feasible in clinical practice. As a result, many 
movement disorder specialists base their diagnosis of RBD solely on the description 
of the typical behaviors by the bed partner of the patient. Studies show that this 
practice results in frequent misdiagnoses and, consequently, overtreatment.6 
Mimicking disorders such as obstructive sleep apnea, confusional arousals and 
nocturnal hallucinations should be excluded, especially because some of these may 
worsen with clonazepam, the first-line treatment of RBD.7 Therefore, there is a need 
for less expensive, easy to use methods to diagnose RBD.
The REM sleep behavior disorder screening questionnaire (RBDSQ) was developed 
as an easy to use screening method.8,9 The scale was created in German and English 
and more recently a Japanese version has been validated.10 Although the question-
naire shows good internal consistency and a high sensitivity (96%) compared to the 
clinical interview, it has a low specificity (56%).8 The REM sleep behavior disorder 
questionnaire Hong Kong (RBDQ-HK) has been developed, tested and validated 
in Chinese patients based on the ICSD-II criteria.11 It was validated in a group of 
PSG-confirmed RBD patients and controls. The overall RBDQ-HK score was sig-
nificantly higher in the RBD group. ROC analysis showed that a cut off score of 18/19 
Abstract
Background
Rapid eye movement (REM) sleep behavior disorder (RBD) is a common 
parasomnia in Parkinson’s disease (PD) patients. The current International 
Classification of Sleep Disorders (ICSD-II) requires a clinical interview combined 
with video polysomnography (video-PSG) to diagnose. The latter is time consuming 
and expensive and not always feasible in clinical practice. Here we studied the use 
of actigraphy as a diagnostic tool for RBD in PD patients.
Methods
We studied 45 consecutive PD patients (66.7% men) with and without complaints of 
RBD. All patients underwent one night of video-PSG and eight consecutive nights 
of actigraphy. Based on previous studies, the main outcome measure was the total 
number of bouts classified as “wake”, compared between patients with (PD+RBD) 
and without RBD (PD- RBD). 
Results
Twenty-three (51.1%) patients had RBD according to the ICSD-II criteria. The total 
number of wake bouts was significantly higher in RBD patients (PD+RBD 73.2±40.2 
vs. PD-RBD 48.4±23.3, p = .016). A cut off of 95 wake bouts per night resulted in a 
specificity of 95.5%, a sensitivity of 20.1% and a positive predictive value of 85.7. Seven 
patients were suspected of RBD based on the interview alone, but not confirmed on 
PSG; six of whom scored below 95 wake bouts per night on actigraphy.
Discussion
PD patients with RBD showed a significantly higher number of bouts scored as 
“wake” using actigraphy, compared to patients without RBD. In clinical practice, 
actigraphy has a high specificity, but low sensitivity in the diagnosis of RBD. The 
combination of actigraphy and previously reported RBD questionnaires may be a 
promising method to diagnose RBD in patients with PD. 
116 117
Actigraphy as a diagnostic toolChapter 5
5
Patients and methods
Design and study population
All patients were recruited from Sleep Medicine Center Kempenhaeghe, a tertiary 
clinic for patients with sleep disorders in the Netherlands. At Kempenhaeghe, PD 
patients with sleep complaints are seen in a dedicated program, including an exten-
sive clinical consultation followed by attended video-PSG that night. Referral reasons 
could be diverse e.g. insomnia, restless legs syndrome, sleep apnea, and thus did 
not only pertain to RBD. We included all consecutive idiopathic PD patients referred 
to the clinic as part of their regular care. All patients satisfied the UK Brain bank criteria 
for PD and were assessed using their usual medication. Data were collected as part 
of the regular medical care. The study was performed according to the guidelines of 
the Medical Ethical Committee of the Radboud University Nijmegen Medical Center. 
All patients gave informed consent to use these data for further study.
Clinical characteristics
Demographic, clinical and disease characteristics were recorded. Disease stage was 
rated using the Hoehn&Yahr staging system.16 The use of levodopa mono therapy, 
dopamine agonist mono therapy and combination therapies was registered. Over-
all dopaminergic treatment was quantified by calculating the Levodopa Equivalent 
Dose (LED) in mg/day.17 In addition, nocturnal dopaminergic treatment was estimat-
ed by the dopaminergic dose taken before going to bed in LED (LED-night). The 
use of anti-depressants -which can cause or aggravate RBD- was actively asked 
for and listed. 
RBD diagnosis
The diagnosis of RBD was made according to the ICSD-II criteria. During the clinical 
interview, the presence of movements and vocalizations during sleep was screened 
for by a sleep specialist experienced with PD (ML and SO). The interview was fol-
lowed by one night of video-PSG. Sleep was scored by laboratory technicians highly 
experienced with scoring polysomnographic recordings in PD patients, and checked 
by a sleep medicine specialist (SO). The presence of REM sleep without atonia was 
determined by quantifying the EMG-signal of the m. submentalis using the “Sin-
Bar-group” criteria.18 Tonic EMG activity was scored in 30 seconds epochs and was 
considered pathological if the amplitude was more than twice the background am-
plitude or exceeded 10 µV in more than 50% of the epoch. Phasic EMG activity was 
scored in 3 seconds mini-epochs and determined to be increased when it contained 
a burst of EMG activity lasting between 0.1 and 5.0 seconds with an amplitude ex-
had moderate sensitivity and specificity.11 More recently Frauscher et al. published 
a validation study of the Innsbruck REM sleep behavior disorders inventory.12 The 
scale had a sensitivity of 91.4% and a specificity of 85.7% for both idiopathic and PD 
related RBD (AUC, 0.886). Interestingly, the scores of patients sleeping alone were 
comparable with patients with a bed partner. 
Table 1.  ICSD-II criteria for REM sleep behavior disorder5
EMG = electromyography , EEG= electroencephalography , PSG= polysomnography, RBD = 
REM sleep behavior disorder, REM = Rapid eye movement
Actigraphy has been suggested as another possible diagnostic tool for RBD. Actigra-
phy may be a useful instrument to obtain general measures such as total sleep time, 
sleep efficiency and wake after sleep onset.13,14 Compared to questionnaires, actig-
raphy should give a more objective representation of actual motor activity during the 
night. In addition, actigraphy is much less expensive and cumbersome compared to 
video-PSG and could be used in a home setting for several days, which may compen-
sate for night-to-night fluctuations in the presence or severity of RBD symptoms. As 
such the use of actigraphy in the diagnosis of RBD seems attractive and the first re-
sults on its use are indeed promising. Naismith et al. found that PD patients with RBD 
had a higher number of bouts scored as “wake” by actigraphy, compared to patients 
without RBD, based on questionnaires.15 In the current study, we sought to confirm 
these findings in a larger group of well-defined PD patients. We compared actigraphy 
outcomes in PD patients with and without RBD, based on the gold standard of a clini-
cal interview in combination with video-PSG. Furthermore we searched for an optimal 
cut-off point to actually implement the use of actigraphy in clinical practice. 
Presence of REM sleep without atonia 
The EMG finding of excessive amounts of sustained or intermittent elevation of sub-
mental EMG tone or excessive phasic submental or (upper or lower) limb EMG twitching. 
At least one of the following is present:
 · Sleep related injurious, or disruptive behaviors by history
 · Abnormal REM sleep behaviors documented during PSG monitoring
 · Absence of EEG epileptiform activity during REM sleep unless RBD can be clearly 
distinguished from any concurrent REM sleep-related seizure disorder.
 · The sleep disturbance is not better explained by any other sleep disorder, medical or 
neurological disorders, mental disorders, medication use, or substance abuse
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Results
Study population
During the study period, 54 PD patients were included. Nine patients were excluded 
from the analysis, one because of technical problems and eight because they had 
less than 10 minutes of REM sleep during the PSG. Twenty-three of the 45 remain-
ing patients (51.1%) were diagnosed with RBD according to the ICSD-II criteria. 
ceeding twice the background activity. REM sleep without atonia was diagnosed 
when more than 18% of 3 second mini-epochs of REM sleep contained increased 
tonic and/or phasic EMG activity.18 Finally, the presence of abnormal REM sleep be-
haviors during PSG was determined using the synchronized video recordings. 
Actigraphy
Actigraphy was performed using the Actiwatch system (Actiwatch AW4, Cambridge 
Neurotechnology Ltd, Cambridgeshire, United Kingdom), a piezoresistive uni-axial 
accelerometer. In agreement with previous studies, the recording device was placed 
on the wrist of the least affected site. Accelerometer signals were digitally sampled 
at a rate of 32 Hz. The actigraphy device is small, comfortable to wear and according 
to the patients did not interfere with their normal sleeping behavior. The first night of 
measurement was done simultaneously with the clinical PSG recording. Sleep and 
wake times were synchronized with PSG “lights off” and “lights on”. After the first night 
in the sleep center the actigraph was worn for seven consecutive nights at home. 
Actigraphy data were analyzed using Sleep Analysis 7.23 software (Cambridge Neu-
rotechnology Ltd, Cambridgeshire, United Kingdom). Epoch length was set on 0.25 
min. Outcome measurements were total sleep time, sleep efficiency, sleep latency, 
number and length of wake bouts and total and mean activity scores. Wake bouts 
during the sleep interval were defined as the total number of continuous blocks in an 
interval where the activity within the epoch was above the sleep threshold and there-
fore scored as “wake”. The wake threshold value (i.e. the number of activity counts 
used to define wake) was set to medium sensitivity, i.e. 40.0 activity counts per epoch. 
Data analysis
Actigraphic measurements were compared between PD patients with and without 
the diagnosis of RBD. Comparisons were tested using independent t-test and chi-
square test depending on the variable. As the Hoehn&Yahr stage was not normal-
ly distributed, a Mann- Whitney U test was used for this variable. Using Pearson’s 
correlation coefficients, associations were analyzed between the number of bouts 
classified as wake by actigraphy and actual wake time during the PSG recording. 
Multiple regression analysis was used to correct for actual wake time according to 
the PSG in the estimation of the number of bouts classified as wake by actigra-
phy. The diagnostic accuracy of the number of wake bouts as a diagnostic tool for 
the presence of RBD, was assessed using ROC analyses. Sensitivity, specificity and 
positive predictive value were calculated. Missing values were <5%, therefore all per-
centages are presented as valid percentages. All data are shown as mean±SD or N 
(%). All results are based on two-tailed tests, with a significance level set at p <.05. 
Table 2.  Clinical and disease characteristics
Results are mean±SD, except if otherwise specified; LED Levodopa Equivalent Dose; LED 
night Levodopa Equivalent Dose taken before going to bed; SSRI Selective Serotonin Re-
uptake Inhibitors; TCA Tricyclic Antidepressants
PD+RBD PD-RBD p
N 23 22
Men (%) 17 (73.9) 13 (59.1) .292
Age (yr) 64.3±9.4 58.1±8.8 .028
Disease duration (yr) 9.5±6.4 4.3±2.8 .024
LED (mg/day) 1089.4±582.9 697.7±563.1 .027
LED night (mg/day) 117.2±51.8 140.6±40.9 .298
Hoehn&Yahr (%) .025
1 - 2 (9.1)
1.5 - 4 (18.2)
2 16 (69.6) 13 (59.1)
2.5 4 (17.4) -
3 3 (13.0) 3 (13.6)
Use of anti-depressants
 · SSRI (%) 4 (17.4) 4 (18.2) .945
 · TCA (%) - 2 (9.1) .139
 · Other (%) 3 (13.0) - .080
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Table 3.  Sleep parameters
Results are mean±SD, except if otherwise specified
% N1 (N2, N3, REM) = percentage in stage N1 (N2, N3, REM) sleep), PLM = periodic limb move-
ment OSAS = obstructive sleep apnea syndrome, RLS = restless legs syndrome
PD+RBD PD-RBD p
N 23 22
PSG results
 · Total sleep time (min) 330.0±51.6 375.6±65.9 .008
 · Sleep efficiency (%) 67.9±8.7 76.3±10.7 .004
 · Sleep latency (min) 13.8±12.2 10.1±8.1 .138
 · % N1 15.2±8.0 10.3±5.2 .037
 · % N2 58.9±11.3 58.0±10.9 .677
 · % N3 13.0±11.3 15.7±9.5 .304
 · % REM 13.0±8.3 15.9±7.2 .118
 · % Wake 30.0±9.4 22.6±10.9 .003
 · Awakenings (no.) 35.3±14.5 28.9±11.1 .109
 · PLM index 36.2±47.2 21.7±31.9 .138
Other sleep diagnoses
 · Insomnia (%) 18 (78.3) 18 (81.8) .766
 · OSAS (%) 6 (26.1) 9 (40.9) .292
 · RLS (%) 6 (26.1) 6 (27.3) .928
 · Hypersomnia (%) 12 (52.2) 8 (36.4) .286
Clinical and disease characteristics 
In table 2, clinical demographic as well as disease characteristics of the study sub-
jects are summarized. Patients with RBD (PD+RBD) were older than those without 
(PD-RBD). Disease severity was higher in patients with RBD with longer disease 
duration and more advanced H&Y disease stage (Table 2). PD+RBD patients used 
higher doses of dopaminergic treatment. In the PD+RBD group ten patients used 
levodopa only and thirteen patients used a combination of levodopa and a dopamine 
agonist. Three patients in the PD-RBD group did not use medication, three were on 
levodopa monotherapy, four on dopamine agonist monotherapy, and twelve used a 
combination of levodopa and a dopamine agonist. Use of anti-depressants was not 
different between groups.
Sleep parameters
Objective sleep quality in PD+RBD patients was lower; patients with RBD spent 
more time awake, and had a shorter total sleep time and lower sleep efficiency (Ta-
ble 3). The prevalence of sleep disorders other than RBD was not different between 
groups (Table 3).
Actigraphy
Actigraphy results are presented in Table 4, both during the first night (i.e. simultane-
ous with the video-PSG) and for the eight consecutive nights in total. In contrast to the 
PSG results, total sleep time and sleep efficiency as estimated by actigraphy were not 
different between patients with and without PD, both during the first night and over-
all eight nights. The total number of bouts classified as wake was 30% higher in the 
PD+RBD compared to PD-RBD group (PD+RBD 73.2±40.2 vs. PD-RBD 48.4±23.3, p 
= .016). This was not the case for the length of the wake bouts. Total activity and mean 
activity scores during sleep were not different either. As several clinical characteristics 
differed between patients with and without PD, comparisons were repeated using 
multiple regression analyses correct for these variables, however this did not change 
the results. Although a correlation was found between number of bouts classified as 
wake and actual wake time (r = .31, p = .039), regression analysis correcting for actual 
wake time still showed a significant effect of the presence of RBD on the number of 
wake bouts (R-squared = 0.18, standardized-beta = 0.31, p = .043). 
Actigraphy in clinical practice
To study the clinical relevance of the previous findings, we calculated the sensitivity, 
specificity and the positive and negative predictive value of actigraphy for the di-
agnosis of RBD. Figure 1 shows the distribution of wake bouts in the PD+RBD and 
PD-RBD groups. A cut-off of 95 wake bouts per night yielded a specificity of 95.5%, 
a sensitivity of 26.1%, a positive predictive value of 85.7% and a negative predictive 
value of 55.3%. Figure 2 shows the ROC curve when using different cut-offs for the 
number of wake bouts during the eight measurement nights. The area under the 
curve was 0.696 with a significance of p = .025. Figure 3 shows the resulting positive 
and negative predictive values according to different prevalence rates of RBD; which 
in our cohort was 51.1%.
We additionally looked at the final diagnosis for patients where the clinical interview 
was incongruent with the final diagnosis of RBD. Based on the clinical interview, sev-
en patients were suspected of having RBD, but did not fulfill the full ICSD-II criteria. 
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Table 5.  Mismatch between RBD diagnosis based on clinical interview and 
  ICSD II criteria
OSAS = obstructive sleep apnea syndrome; PLMD = periodic leg movement disorder; RLS = 
restless legs syndrome
PD patients with clinical interview suspicious for RBD 
but not confirmed by ICSD II criteria
Study number Final diagnoses
Number of wake bouts 
according to actigraphy
21 OSAS 52.4
24 Insomnia, PLMD 100.7
29 Insomnia, PLMD, hallucinations 19.4
32 Insomnia, RLS 56.3
48 Insomnia 28.0
71 Insomnia, RLS, PLMD 83.5
73 Insomnia, OSAS 42.1
PD patients with clinical interview negative for RBD 
but with diagnosis based on ICSD II criteria
Study number Other diagnoses next to RBD
Number of wake bouts 
according to actigraphy
1 Insomnia, OSAS, RLS 108.1
12 Insomnia, RLS, PLMD 92.3
16 Insomnia 59.8
44 Insomnia 25.7
45 Insomnia, RLS, PLMD 189.3
65 Insomnia, RLS 32.9
75 Insomnia, PLMD 71.5
All but one of these patients had sleep initiation or maintenance problems (insom-
nia); two were diagnosed with obstructive sleep apnea syndrome, two had rest-
less legs syndrome, three showed an increased level of periodic leg movements, 
and one suffered from nocturnal hallucinations (Table 5). Six of the patients had a 
wake bout count lower 95 (Table 5). Seven patients did not have a clinical history of 
RBD, but PSG findings allowed an RBD diagnosis according to the ICSD-II criteria. In 
these patients there was either no bed partner, or the bed partner claimed to be al-
ways fast asleep not noticing any abnormal behavior of the patient. Additional sleep 
diagnoses in this group are listed in Table 5. The actigraphy-based number of wake 
bouts in this group was highly diverse, showing no consistent direction.
Table 4. Actigraphy results 
\
Results are mean±SD
PD+RBD PD-RBD p
N 23 22
Actigraphy night 1
 · Total sleep time (min) 396.5±72.0 429.1±58.4 .103
 · Sleep efficiency 82.7±12.3 87.6±8.7 .133
 · Sleep latency (min) 3.3±6.5 2.4±4.7 .580
 · No wake bouts 78.4±46.1 49.5±22.2 .011
 · Length wake bouts (min) 1.1±0.5 1.2±0.6 .488
 · Total activity score 12943.8±11432.2 10132.6±6847.6 .325
 · Mean activity score 6.9±5.7 5.4±3.9 .299
Actigraphy mean of 8 nights
 · Total sleep time (min) 397.4±91.1 389.5±64.1 .738
 · Sleep efficiency 78.4±14.6 84.7±9.5 .097
 · Sleep latency (min) 10.0±10.6 5.8±10.3 .187
 · No wake bouts 73.2±40.2 48.4±23.3 .016
 · Length wake bouts (min) 1.3±0.6 1.4±0.5 .689
 · Total activity score 17885.2±14375.8 12613.9±9793.2 .160
 · Mean activity score 10.4±11.5 7.2±5.4 .231
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Figure 3.  Prevalence and predictive value
Discussion
Solely using the clinical interview to assess the possible presence of RBD in PD pa-
tients, often results in misdiagnoses. However, even judicious use of video-PSG is 
costly and not always feasible. Therefore, there is a clear need for new screening 
tools for RBD. Our results show that using actigraphy, the number of bouts classified 
as “wake” is significantly higher in PD patient with RBD compared to PD patients 
without. Accordingly, we show that actigraphy has a very high specificity and a good 
positive predictive value for diagnosing RBD in PD patients.
Wake bouts as scored by actigraphy were previously suggested as a possible useful 
marker in the diagnostic workup of RBD in PD: our findings are in agreement with 
Naismith et al., who studied 22 patients with 14 consecutive nights of actigraphy.15 
However, the actual number of wake bouts was almost twice as high in our patient 
group, compared to theirs. Since sensitivity settings of the actigraphs were the same, 
this difference may have been caused by different epoch length settings, which was 
0.25 min in our study and 0.50 in the study of Naismith et al..15 In addition, we used 
video-PSG in combination with a clinical interview by a sleep medicine specialist as 
the gold standard for the diagnosis of RBD, instead of questionnaires. 
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of idiopathic RBD: although clear studies about the prevalence of RBD in the general 
elderly population are lacking, rates are estimated between 0.38% and 0.50%, lead-
ing to a positive predictive value below 5%.19,20
Contrary to the high specificity and low sensitivity of actigraphy, previous research 
showed that RBD questionnaires have a high sensitivity and a somewhat low spec-
ificity.8,10-12 Combining actigraphy and RBD questionnaires could therefore lead to a 
more accurate diagnosis of RBD. The combination of these two tools could reduce 
the need for video-PSG even more. Future research should focus on the clinical 
value of using a combination of both methods.
Our study used the ICSD-II criteria for the diagnosis of RBD. These criteria are not 
unambiguous unfortunately. They include presence of atonia during REM sleep, 
which represents a pathological increase of either phasic EMG activity, tonic EMG 
activity or both. Cut-off points to diagnose pathological increased phasic and tonic 
EMG activity are not mentioned in the criteria however, and no agreement has been 
reached on this point among international research groups. Here, we therefore ad-
opted the criteria developed by the SinBar group, although several other visual and 
computerized scoring methods have been mentioned in literature.2,18,21-26
Conclusion
PD patients with RBD showed a significantly higher number of bouts scored as 
“wake” using actigraphy, compared to patients without RBD. In clinical practice, ac-
tigraphy has a high specificity, but low sensitivity in the diagnosis of RBD. According 
to our results and previous studies on the use of RBD questionnaires, the combi-
nation of both tools could be a promising method to diagnose RBD in PD patients, 
leading to a decrease in the need for the costly and time-consuming video-PSG. 
Previous studies have suggested that actigraphy is an useful method to measure sleep 
quality in PD patients. Correlations were found between actigraphy and total sleep 
time, wake after sleep onset and subjective complaints about nocturnal sleep.13,14 Our 
results however showed a difference between total sleep time and sleep efficiency 
measured with actigraphy and PSG. Although the actigraph was measured on the 
least affect side, we cannot exclude that the presence of tremor, on-off fluctuations 
and/or dyskinesias may have influenced the results. More research is needed to study 
the influence of PD motors symptoms on actigraphic results during the night.
There was no increase in either total or mean activity levels during sleep, which could 
have been expected in patients with REM related movements. However, as RBD as-
sociated movements lead to activity well above the threshold that is represented as 
“sleep” by actigraphy, they are almost always scored as “wake bouts” rather than in-
creased activity during sleep. Variables other than the presence of RBD may have in-
fluenced the number of bouts classified as wake. The periodic limb movement index 
was, although not significantly, higher in the PD+RBD group compared to the PD-
RBD group. The lack of significance could be caused by a large difference in variance. 
Periodic limb movements can cause sleep disturbances and therefore increase the 
number of wake bouts. Our groups were not matched with respect to age, disease 
duration, disease stage and medication use, and these factors may also influence 
sleep. However, regression analyses correcting for these clinical characteristics and 
PSG-determined actual wake time during the night, still showed a significant differ-
ences in the number of wake bouts between groups. These findings suggest that the 
increased number of wake bouts is primarily the result of the presence of RBD. 
Results showed that using an epoch length of 0.25 min and a cut-off of 95 wake 
bouts per night, actigraphy is a highly specific tool for RBD in PD patients, albeit with 
a low sensitivity. As the prevalence of RBD in PD ranges between 30% and 60%, 
actigraphy has a positive predictive value between 70 and 90% which is reason-
able.1-3 Based on a semi-structured clinical interview alone, we found seven patients 
incorrectly suspected of having RBD. Of these, only one patient scored above the 
threshold of 95 wake bouts per night. Therefore, these results show an additional 
value of using actigraphy next to a clinical interview in the diagnostic trajectory of 
RBD. Seven patients had no clinical history of RBD-like behavior but still fulfilled the 
diagnostic PSG criteria of RBD, and actigraphy did not differentiate these patients 
from the group without RBD. Actigraphy therefore mainly has a role in combination 
with at least a clinical suspicion of RBD, rather than a screening instrument in PD 
patients without complaints of RBD. Actigraphy should not be used in the diagnosis 
128 129
Actigraphy as a diagnostic toolChapter 5
5
haviour disorder in Parkinson’s Disease. 
Clinical neurology and neurosurgery 
2010;112:420-3.
16. Hoehn MM, Yahr MD. Parkinsonism: on-
set, progression and mortality. Neurology 
1967;17:427-42.
17. Tomlinson CL, Stowe R, Patel S, Rick C, 
Gray R, Clarke CE. Systematic review of 
levodopa dose equivalency reporting 
in Parkinson’s disease. Movement dis-
orders : official journal of the Movement 
Disorder Society 2010;25:2649-53.
18. Frauscher B, Iranzo A, Gaig C, et al. Nor-
mative EMG values during REM sleep for 
the diagnosis of REM sleep behavior dis-
order. Sleep 2012;35:835-47.
19. Ohayon MM, Caulet M, Priest RG. Violent 
behavior during sleep. The Journal of 
clinical psychiatry 1997;58:369-76; quiz 
77.
20. Chiu HF, Wing YK, Lam LC, et al. 
Sleep-related injury in the elderly--an 
epidemiological study in Hong Kong. 
Sleep 2000;23:513-7.
21. Lapierre O, Montplaisir J. Polysomno-
graphic features of REM sleep behav-
ior disorder: development of a scoring 
method. Neurology 1992;42:1371-4.
22. Arnulf I, Merino-Andreu M, Bloch F, et 
al. REM sleep behavior disorder and 
REM sleep without atonia in patients with 
progressive supranuclear palsy. Sleep 
2005;28:349-54.
23. Ferri R, Manconi M, Plazzi G, et al. A 
quantitative statistical analysis of the sub-
mentalis muscle EMG amplitude during 
sleep in normal controls and patients with 
REM sleep behavior disorder. Journal of 
sleep research 2008;17:89-100.
24. Mayer G, Kesper K, Ploch T, et al. Quanti-
fication of tonic and phasic muscle activity 
in REM sleep behavior disorder. Journal 
of clinical neurophysiology : official pub-
lication of the American Electroencepha-
lographic Society 2008;25:48-55.
25. Bliwise DL, Trotti LM, Greer SA, Juncos 
JJ, Rye DB. Phasic muscle activity in sleep 
and clinical features of Parkinson disease. 
Annals of neurology 2010;68:353-9.
26. Montplaisir J, Gagnon JF, Fantini ML, 
et al. Polysomnographic diagnosis of 
idiopathic REM sleep behavior disor-
der. Movement disorders : official jour-
nal of the Movement Disorder Society 
2010;25:2044-51.
References
1. Comella CL, Nardine TM, Diederich NJ, 
Stebbins GT. Sleep-related violence, 
injury, and REM sleep behavior disor-
der in Parkinson’s disease. Neurology 
1998;51:526-9.
2. Gagnon JF, Bedard MA, Fantini ML, et al. 
REM sleep behavior disorder and REM 
sleep without atonia in Parkinson’s dis-
ease. Neurology 2002;59:585-9.
3. Gjerstad MD, Boeve B, Wentzel-Larsen 
T, Aarsland D, Larsen JP. Occurrence and 
clinical correlates of REM sleep behaviour 
disorder in patients with Parkinson’s dis-
ease over time. J Neurol Neurosurg Psy-
chiatry 2008;79:387-91.
4. De Cock VC, Vidailhet M, Leu S, et al. Res-
toration of normal motor control in Par-
kinson’s disease during REM sleep. Brain 
2007;130:450-6.
5. American Academy of Sleep Medicine. 
The International Classification of Sleep 
Disorders. 2005;Second edition.
6. Eisensehr I, v Lindeiner H, Jager M, No-
achtar S. REM sleep behavior disorder in 
sleep-disordered patients with versus 
without Parkinson’s disease: is there a 
need for polysomnography? J Neurol Sci 
2001;186:7-11.
7. Iranzo A, Santamaria J. Severe obstruc-
tive sleep apnea/hypopnea mimick-
ing REM sleep behavior disorder. Sleep 
2005;28:203-6.
8. Stiasny-Kolster K, Mayer G, Schafer S, 
Moller JC, Heinzel-Gutenbrunner M, 
Oertel WH. The REM sleep behavior dis-
order screening questionnaire--a new 
diagnostic instrument. Movement dis-
orders : official journal of the Movement 
Disorder Society 2007;22:2386-93.
9. Chahine LM, Daley J, Horn S, et al. Ques-
tionnaire-based diagnosis of REM sleep 
behavior disorder in Parkinson’s dis-
ease. Movement disorders : official jour-
nal of the Movement Disorder Society 
2013;28:1146-9.
10. Sasai T, Matsuura M, Wing YK, Inoue Y. 
Validation of the Japanese version of 
the REM sleep behavior disorder ques-
tionnaire (RBDQ-JP). Sleep medicine 
2012;13:913-8.
11. Li SX, Wing YK, Lam SP, et al. Validation 
of a new REM sleep behavior disorder 
questionnaire (RBDQ-HK). Sleep medi-
cine 2010;11:43-8.
12. Frauscher B, Ehrmann L, Zamarian L, et 
al. Validation of the Innsbruck REM sleep 
behavior disorder inventory. Movement 
disorders : official journal of the Move-
ment Disorder Society 2012;27:1673-8.
13. Stavitsky K, Saurman JL, McNamara P, 
Cronin-Golomb A. Sleep in Parkinson’s 
disease: a comparison of actigraphy and 
subjective measures. Parkinsonism & re-
lated disorders 2010;16:280-3.
14. Maglione JE, Liu L, Neikrug AB, et al. 
Actigraphy for the assessment of sleep 
measures in Parkinson’s disease. Sleep 
2013;36:1209-17.
15. Naismith SL, Rogers NL, Mackenzie 
J, Hickie IB, Lewis SJ. The relation-
ship between actigraphically defined 
sleep disturbance and REM sleep be-
130 131
Summary, 
general 
discussion 
and future 
perspectives6  
◄ contents  
132 133
Summary, general discussion and future perspectivesChapter 6
6
Sleep and sleep disorders in Parkinson’s disease
In Chapter 2.1 we describe that sleep disorders are not only common but also very 
diverse: often more than one sleep problem is present in a patient with PD. This could 
lead to difficulties in the recognition and separation of sleep disorders being pres-
ent. Especially since consultation time is usually short in clinical practice and multiple 
other PD-related problems should also be discussed. For a neurologist not having 
much experience with sleep disorders, there is a considerable risk of under-recogni-
tion and undertreatment of these problems. Sleep however matters much to the PD 
patient. In Chapter 2.2 we studied the importance of sleep compared to other symp-
toms and daily limits for the PD patient by using a priority list. Seventy percent of the 
153 PD patients had disturbed sleep. About a third of them (37.9%) prioritized sleep as 
an item they wanted to discuss during their visit to the movement disorder specialist. 
Sleep was the 6th item on the list of 23 potential items. Patients who prioritized sleep 
had significantly worse sleep quality (PSQI 9.3±3.8 vs. 5.5±2.8, p < 0.001), however, 
patients who prioritized sleep had exactly the same Epworth Sleepiness Scale scores 
as patients who did not (both 8.0±5.2, p = .996). This could indicate that daytime 
sleepiness is a less important issue than other sleep-related phenomena. 
These results show that sleep is an important issue for PD patients and that pres-
ence of poor sleep quality is a reason to ask for medical attention. Interestingly, not all 
patients with poor sleep quality marked sleep as an item on their priority list to dis-
cuss with their physician. One explanation is that patients do not always recognize 
their sleep as being poor. They may not always be aware that their sleep disturbance 
is related to their PD, and importantly, they may not realize that possible treatment 
options exists. Another possible explanation is that, although sleep is disturbed, oth-
er issues are more important at the time of consultation. Therefore patients do not 
include sleep among the five most important issues to discuss with their physician. 
This theory is supported by the fact that patients with the poorest sleep quality (PSQI 
>10) did prioritize sleep. Excessive daytime sleepiness (EDS) alone was no reason to 
prioritize sleep for the majority of patients. Next to the other explanations, this could 
also be caused by the fact that patients, do not perceive their EDS as a sleep prob-
lem. Symptoms are present during the day and patients may not associate EDS with 
night time disturbances. Moreover, patients often consider EDS equivalent to phys-
ical fatigue, which is in fact a different symptom. Conversely, some patients merely 
complain of being “fatigued” to their doctor, whereas in fact they intend to say that 
they have EDS. Clearly, this requires careful and proactive history taking by the phy-
sician or Parkinson nurse specialist.
I first present the main findings of the various original studies, and then place these 
findings within an overarching context.
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Impaired bed mobility in Parkinson’s disease
Although important for many PD patients, the subject of impaired bed mobility 
(IBM) and sleep problems have so far received little attention in research. In Chapter 
3.1 we showed a clear detrimental influence of difficulties turning around in bed on 
the quality of nocturnal sleep. We studied a large cohort of 240 PD patients, focusing 
specifically on the relation between sleep quality on one hand, and the presence 
and frequency of impaired bed mobility on the other. Impaired bed mobility was 
present in 56.3% of patients. The prevalence of poor sleep was higher in patients 
with impaired bed mobility, as reflected by significantly higher mean PSQI scores 
(PD+IBM 7.7±4.1 vs.PD-IBM 6.1±3.4, p = .001). When we corrected the results for 
age, disease duration, H&Y stage and LED, presence of impaired bed mobility still 
had a significant effect on PSQI total score (R-squared = 0.066, standardized-beta = 
0.163, p=0.026). The relation between the frequency of difficulties turning around in 
bed and sleep quality showed a linear trend (contrast estimate 1.9, p=0.001). 
We studied the influence of impaired bed mobility on objective sleep parameters 
in Chapter 3.2. We compared the influence of subjective impaired bed mobility on 
objective sleep quality in patients with PD. We found that PD patients who complain 
of subjective impaired bed mobility had a significantly diminished sleep efficiency 
(PD+IBM 63.5% (26.2-85.6) vs. PD-IBM 78.4% (54.8-92.6), p<.001) and a short-
er total sleep time compared to patients without complaints (PD+IBD 298.0 min 
(103.0-419.0) vs. PD-IBM 379.6 min (243.0-530.0), p = .001). 
Impaired bed mobility and sleep quality
Although in clinical practice impaired bed mobility is considered to play an import-
ant role in diminished sleep quality in PD patients, the subject has received little 
attention in research so far. Findings by van Hilten et al. suggest a link between sleep 
maintenance problems and problems turning around in bed, as the results showed 
a higher frequency of problems turning around in bed in PD patients compared to 
controls. This was only the case for PD patients and controls with sleep maintenance 
problems, but not patients with sleep initiations problems.4 These results, however, 
could also be explained by the co-occurrence of both insomnia and impaired bed 
mobility in PD, without a causal relation. Gjerstad et al. found that problems turning 
around in bed increased with the duration of PD over a study period of eight years.5 
During this period the prevalence of insomnia did not increase, which suggests that 
there is no correlation between both entities. Stack et al. studied recumbent turn-
ing strategies in 39 PD patients, seven of whom were completely unable to turn in 
How to recognize sleep problems in PD patients?
Previous studies have shown that presence of sleep disorders influences quality of 
life in PD patients.1-3 Therefore we should prevent under-recognition and under-
treatment of this problem. In both Chapter 2.1 and Chapter 2.2 we offer practical 
tools which could help in the detection and diagnosis of sleep problems. In Chapter 
2.2 we showed that using a priority list can help highlighting the presence of import-
ant sleep issues to discuss during the consultation. In Chapter 2.1 we recommend 
a useful chart which separates the possible sleep disorders present and classifies 
them in four major categories: daytime sleepiness, nocturnal motor symptoms, 
sleep-related breathing disorders and disorders of insomnia. In just a few minutes, 
using a set of recommended questions, the treating neurologist can identify if a pa-
tient is suspected of having any of the sleep disorders. Second, we provide a list 
pointing out which additional information is necessary to make a final diagnosis and 
to decide whether or not referral to a sleep center is needed. 
One could argue in favor of sending every PD patient to a specialist sleep center at 
least once, to prevent the under-recognition and undertreatment of sleep problems. 
Especially since Chapter 2.2 shows the importance of sleep to the PD patient.
A diagnostic flow chart can facilitate the early detection of sleep disturbances 
in PD. 
A priority list can be used to prioritize patient centered quality of life issues and 
detect sleep problems in PD patients.
Every PD patient deserves to see a sleep medicine specialist at least once. 
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showed that overall, PD patients had fewer movements and turning events were 
almost 20 sec longer in PD patients. Our results did not show a difference between 
body position changes per hour in PD patients compared to controls. We did find 
a reduced number of body position changes during sleep between PD+IBM and 
PD-IBM. Remarkably, this difference was only present during sleep and not during 
wake time. This is in contrast to what could be expected since PD patients complain 
of having impaired bed mobility when lying awake. No relation between sleep effi-
ciency and impaired bed mobility could be found, suggesting that the insomnia is 
influenced by the subjective feeling rather than the actual body position changes. 
The precise mechanism of impaired bed mobility is not clear. Problems turning in 
bed are probably a part of the overall axial motor impairments in PD. Rigidity as well 
as bradykinesia are considered to play a role. Steiger et al. found an association be-
tween difficulty turning in bed and both axial rigidity and whole body bradykinesia 
in 19 PD patients.10 After levodopa treatment the turning in bed improved as well as 
the axial rigidity and bradykinesia. This however is in contrast to the findings of Lakke 
et al. describing patients with turning difficulties when lying recumbent.11 Levodopa 
therapy improved rigidity and bradykinesia, but turning difficulties remained. The 
authors stated that these turning problems were probably caused by “axial apraxia” 
rather than rigidity or bradykinesia in these patients. Our results show that there is 
a group of patients with a small number of body position changes during the night, 
but without subjective complaints. To get more insight into the mechanism of im-
paired bed mobility this particular group should be studied further. 
Nocturnal body movements and their influence should be studied in more detail in 
both the general population and PD patients in particular. Actigraphy does not seem 
to be the best method to register body movements, since activity levels do not give 
any information about speed, direction or patterns of a movement. Rather than ac-
tigraphy more advanced tools should be used, that register actual movement during 
sleep. As such one could think of video monitoring and analysis to observe body po-
sition changes during the night. Also body mobility measured with a compression 
sensor in the bed could be an option. When using accelerometers, more advanced 
devices using tri-axial accelerometers should be used. Also the best registration 
side is discussable; the best results are probably established by using a combination 
of sensors on the trunk as well as the extremities. A correlation between movements 
and sleep quality can be made preferably with objective measurement techniques 
such as PSG. 
bed.6 They found that sleep initiation and maintenance problems were comparable 
between both groups. A major problem of these studies is that PD patients were 
compared with healthy controls. Research has however showed that sleep quali-
ty is different in both groups. Therefore the studies do not actually imply whether 
sleep quality is diminished by the presence of impaired bed mobility or if other fac-
tors, such as the PD itself, are influencing sleep. Our studies were the first to find an 
association between sleep disruption and impaired bed mobility within a group of 
PD patients. We showed that both subjective sleep quality measured with ques-
tionnaires as well as objective sleep quality based on PSG findings are worse in PD 
patients with complaints of impaired bed mobility. 
Body position changes in PD
In Chapter 3.2 we also objectified the complaint of impaired bed mobility. We com-
pared actual body position changes between 24 PD patients with and 20 without 
complaints of impaired bed mobility and 44 healthy controls. Our results showed 
only a marginally significant difference between turns during the total night (PD 7.6/h 
(0.0-19.1) vs. controls 8.8/h (2.0-47.6), p = .046). Furthermore, no significant differ-
ence was found in number of turns between PD patients with and without com-
plaints of impaired bed mobility (PD+IBM 6.6/h (0.3-15.0) vs. PD-IBM 8.1/h (0.0-
19.1), p = .099). When focusing on actual body position changes during sleep alone 
the results did show a reduced frequency in patients with impaired bed mobility 
(PD+IBM 0.4/h (0.0-1.8) vs. PD-IBM 1.4/h (0.0-4.6), p=.015). There was a broad 
range in the frequency of body position changes however, and even subjects with 
almost no shifts did not necessarily have impaired sleep quality. More importantly, 
no correlation was found between turns during sleep and sleep efficiency (PD+IBM 
R squared = 0.043, p = .900). 
A limited number of studies has focused on nocturnal activity in PD patients during 
sleep. Two studies reported increased nocturnal activity levels comparing PD pa-
tients to controls.7,8 This probably does not directly imply that PD patients have high-
er activity during sleep. More likely this is caused by increased sleep fragmentation 
leading to more wake states during the night. We did not find any difference in ac-
tivity level between PD+IBM and PD-IBM as measured with actigraphy. The con-
trols, however, did not have actigraphy, so a comparison between PD and controls 
could not be made. One previous study focused on actual body position changes 
during sleep in PD. Laihinen et al. compared bed mobility in nine PD patients and 11 
neurological healthy controls, using a static charge sensitive bed.9 Movements were 
distributed over duration classes of < 5 sec, 5-10 sec, 11-15 sec, >15 sec. The results 
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Nocturnal movements in the preclinical phase of  
Parkinson’s disease 
Although previous studies suggested differences in nocturnal mobility between PD 
patients and controls, the study of Chapter3.2 did not show increased activity lev-
els during the night in PD patients, and also no decreased frequency of nocturnal 
turns. Body position changes during the night may, however, have different patterns 
compared to controls. These changes may also precede the onset of PD and could 
therefore be interesting to study as an early PD marker. In Chapter 4 we compared 
nocturnal movements in 11 PD patients and 13 healthy controls and 33 non-PD in-
dividuals with a potential high risk for future development of the disease (HR-PD). 
All patients were investigated within the framework of the PMPP study (Progression 
Markers in the Premotor Phase of Parkinson’s Disease).15,16 In brief, individuals de-
fined as HR-PD had hyperechogenicity of the substantia nigra in addition to con-
comitant risk or prodromal markers of PD. These subjects had at least one symptom 
defined as either (a) or (b): (a) one PD cardinal motor sign assessed by the Unified 
Parkinson’s Disease Rating Scale (UPDRS-III) motor part, (b) two of the following 
prodromal/risk markers: prevalence of depression or history of depression, hypos-
mia, one-sided reduced arm swing, positive family history of PD.17-19 All controls had 
normal echogenicity of the substantia nigra, no signs of acute psychiatric diseases 
and a negative family history of PD.19,20 The results show that with respect to general 
movement assessment, mean acceleration was lower in PD patients compared to 
controls. Again the frequency of axial turns did not significantly differ between both 
groups, but the distribution and pattern of the axial turns did: total size of axial turns 
was smaller (PD 32.6° (17.5-46.9) vs. controls 46.72° (22.7-73.9), p < .001) and du-
ration of turns was shorter (PD 5.7 s (4.1-8.8) vs. controls 6.96 s (5.6-10.2), p = .001) 
in PD patients. No differences were found between mean acceleration in HR-PD 
patients and controls. Furthermore, characteristics of axial turns were not different.
In agreement with the findings of Chapter 3 no differences in frequency of nocturnal 
movements were found between PD patients and controls. Some aspects of noctur-
nal movements were different in PD patients however. In general, our data suggest 
that PD patients may attempt to turn, but are not able to reach the full size of these axial 
movements. Although size and duration of movements were altered in the PD group, 
the speed level of movements was similar to that of healthy controls. Previous studies 
on nocturnal movements are mentioned above, none of them focused on the pattern 
of movements we studied in Chapter 4, therefore a direct comparison with other stud-
ies cannot be made. From our findings, one could hypothesize that PD-related axial 
Previous studies on Parkinson medication show improvement on subjective bed 
mobility when using the administered drugs.12,13 However, since our results show no 
actual differences in nocturnal movement in PD+IBM en PD-IBM, the exact physiol-
ogy of this improvement is unclear. Does the medication lead to an actual improve-
ment of bed mobility, or are improvements more subjective because of a sedative 
effect. A more multidisciplinary approach to bed mobility also suggests an improve-
ment of sleep when using physiotherapeutic turning strategies in bed. Especial-
ly the Dutch guideline, but also the recent European guideline partly focus on im-
provement of bed mobility.14 The expert opinion of physiotherapist in the field of PD 
describes an subjective improvement of sleep quality when using these strategies. 
More research is needed to clarify this problem, preferably comparing medication 
with physiotherapy. The use of video registration or tri-axialaccelerometry focusing 
on the turning strategies could be useful to get more insight into this problem. 
Subjectively impaired bed mobility is negatively associated with both subjec-
tive and objective quality of nocturnal sleep. Whether or not this reflects a true 
causal relationship or a mere association requires further study.
PD patients with complaints of impaired bed mobility move less during sleep 
compared to PD without complaints, but not when lying awake at night.
Sleep seems to be disrupted by the subjective feeling of impaired bed mobility 
rather than actual diminished body position changes. 
Activity levels between PD with and without impaired bed mobility are not dif-
ferent.
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Actigraphy as a diagnostic tool in REM sleep behavior 
disorder 
Assessing the presence of RBD in PD patients based on the clinical interview alone 
often results in misdiagnosis. According to the current diagnostic criteria, the diag-
nosis of RBD requires a clinical interview and video polysomnography (v-PSG).25 In 
clinical practice, however, this is not always feasible, since it is time consuming and 
expensive. Therefore there is a need for less expensive, easy to use devices to diag-
nose RBD. In Chapter 5 we studied the use of actigraphy as a diagnostic tool for RBD 
in PD patients. We studied 45 PD patients with and without the clinical diagnosis of 
RBD. The diagnosis was based on the clinical interview accompanied with v-PSG, 
according to the ISCD-II criteria. The main outcome measure was the total num-
ber of bouts classified as “wake”, compared between patients with (PD+RBD) and 
without (PD- RBD) RBD. The total number of wake bouts was significantly higher 
in RBD patients (PD+RBD 73.2±40.2 vs. PD-RBD 48.4±23.3, p = .016). A cut off of 
95 wake bouts per night resulted in a specificity of 95.5%, a sensitivity of 20.1% and 
a positive predictive value of 85.7%. Based on the clinical interview, seven patients 
were suspected of having RBD, but they did not fulfill the full ICSD-II criteria. All but 
one of these patients had sleep initiation or sleep maintenance problems (insomnia); 
two were diagnosed with obstructive sleep apnea syndrome, two had restless legs 
syndrome, three showed an increased level of periodic leg movements, and one 
reported nocturnal hallucination. Six of the patients had a wake bout count lower 95. 
Wake bouts as scored by actigraphy have been suggested before as a possibly use-
ful outcome measure in the diagnostic workup of RBD in PD patients: our findings 
are in agreement with Naismith et al., who studied 22 patients during 14 consecutive 
nights with actigraphy.26 A major difference between our study and that of Naismith 
et al. was the fact that the actual number of wake bouts was almost twice as high in 
our patient groups compared to theirs. Since the sensitivity setting of the devices 
the same, this could be caused by difference in epoch length settings, which was 
0.25 min in our study, and 0.50 in the study of Naismith et al.26 In addition, we used 
v-PSG in combination with a clinical interview by a sleep medicine specialist as the 
gold standard for the diagnosis of RBD, instead of questionnaires. 
Our results show that using actigraphy, the number of bouts classified as “wake” is 
significantly higher in PD patient with RBD compared to PD patients without. Ac-
cordingly, we show that actigraphy has a high specificity and a good positive pre-
dictive value for diagnosing RBD in PD patients. In our study we also focused on the 
motor dysfunction during the night influences the size of the movements rather than 
its speed. We can only speculate about the cause of these differences. Both rigidity as 
well as bradykinesia may contribute to these changes, as well as the difficulty that PD 
patients have in generating complex, sequential movements or axial synergies.21,22 
Future research should focus on this subject. Including more detail information on 
diurnal and nocturnal movements may lead to a more precise explanation, which can 
lead to more targeted therapy options. Based on questionnaires, sleep quality was 
not different between the three groups. In the study of Chapter 4 we however did not 
include objective sleep measurements. Especially in the PD group it would be inter-
esting to study the influence of the movement patterns changes on sleep structure.
 
Our second hypothesis stated that changes in nocturnal movement patterns might 
occur already in non-PD individuals with potential high risk for future development 
of the disease and may thus potentially serve as prodromal makers of the disease. 
We could not prove this hypothesis. We know, however, that nocturnal movements 
change somewhere in the course of progression of the clinically overt motor phase 
of PD. For example, rapid eye movement (REM) sleep behavior disorder (RBD) is a 
sleep disorder known to predict future onset of PD. After a period of 5 years around 
28% to 45% of idiopathic RBD patients converted to PD and 40% to 65% after a period 
of 10 years.23,24 Patients with RBD have overt movements during the normally, atonic 
REM phase of sleep. This suggests that RBD results in changed motor patterns in 
high risk individuals. Longitudinal assessment is necessary to further follow up these 
high risk individuals to study if changes precede the diagnosis of PD, and potentially 
serve as a high risk marker. However the mechanism of RBD is still not clear and 
movements during REM sleep could not be related to other movements in PD.
 Not the frequency but the mean acceleration, size and duration of axial move-
ments are altered in the overt motor phase of PD. 
Nocturnal motor patterns in individuals who are at high risk for future develop-
ment of PD are comparable with healthy controls. 
Nocturnal motors patterns, as these can be analyzed currently, are not a useful 
biomarker for the early detection of PD. 
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Conclusions and future perspectives
Our studies show that sleep is an important issue for the patient with PD. Poor sleep 
quality is a reason to ask for medical attention. Problems turning around in bed re-
sulting in impaired bed mobility have a negative influence on both subjective as well 
as objective sleep parameters. Interestingly, we could not find a correlation between 
body position changes and sleep efficiency during the night, suggesting the poor 
sleep quality is caused by the complaint of impaired bed mobility rather than the ac-
tual body position changes. Not frequency but speed and duration of axial nocturnal 
movements are altered in patient with PD. However when these changes appear 
during the disease process is not clear, they are not present yet in individuals with 
some minor complaints of PD. Actigraphy has an additional value to the clinical in-
terview alone in the diagnostic trajectory of RBD in PD patients. More research on 
the role of body position changes on sleep quality in necessary in PD patients as well 
as in the healthy population. This will finally lead to better and more individualized 
treatment of sleep problems in PD patients. 
use of actigraphy in clinical practice. Our results show that using an epoch length 
of 0.25 min and a cut-off of 95 wake bouts per night, actigraphy is a highly specific 
tool, albeit with a low sensitivity. Based on a semi-structured clinical interview alone, 
we found seven patients incorrectly suspected of having RBD. Of these, only one 
patients scored above the threshold of 95 wake bouts per night. Therefore, these 
results show an additional value of using actigraphy next to a clinical interview in the 
diagnostic trajectory of RBD to exclude its presence. 
Contrary to the high specificity and low sensitivity of actigraphy, RBD questionnaires 
had a high sensitivity (96%) and a somewhat low specificity (56%).27-30 Combining 
actigraphy and RBD questionnaires could therefore lead to a more accurate diag-
nosis of RBD. The combination of these two tools could reduce the need for v-PSG, 
which is more complex and less readily available. Future research should study if a 
combination of both methods could optimize the diagnosis of RBD in PD patients in 
clinical practice.
Measured with actigraphy, the number of bouts classified as wake is signifi-
cantly higher in PD patients with RBD compared to PD patients without RBD.
A cut off of 95 wake bouts per night results in a specificity of 95.5%, a sensitivity 
of 20.1% and a positive predictive value of 85.7%.
Actigraphy has an additional value next to the clinical interview alone in the 
diagnostic trajectory of RBD in PD patients. 
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Ziekte van Parkinson
De ziekte van Parkinson is een progressieve hersenziekte die zich kenmerkt door 
problemen in het bewegen. De criteria om de diagnose te stellen bestaan uit ver-
traging van bewegingen (bradykinesie) in combinatie met stijfheid (rigiditeit), be-
ven (tremor), of afwijkende houdingsreflexen. Naast de bewegingsproblemen zijn 
er ook andere symptomen die niet met bewegen te maken hebben aanwezig bij 
parkinsonpatiënten. Deze klachten hebben soms meer invloed op de kwaliteit van 
leven dan de bewegingsklachten. Hierbij kan gedacht worden aan problemen met 
de reuk, autonome functiestoornissen zoals obstipatie en urine-incontinentie, de-
pressiviteit en slaapproblemen. 
Slaap
Slapen in belangrijk voor elk individu. Tijdens de slaap rust het lichaam uit en wor-
den ervaring van de dag opgeslagen in het geheugen. Te weinig slaap of slechte 
slaapkwaliteit leidt tot problemen overdag zoals ongewild in slaap vallen, concen-
tratie en geheugenproblemen. Slaap kan worden gemeten met polysomnografie 
(PSG), dit zijn metingen van een combinatie van hersenactiviteit (EEG), spieractiviteit 
(EMG), oogbewegingen (EOG) en cardiorespiratoire parameters. 
Af en toe slecht slapen is niet ongebruikelijk, maar meerdere slechte nachten ach-
ter elkaar zouden kunnen passen bij een slaapstoornis. Slaap kan verstoord wor-
den door externe factoren zoals geluid, stress en pijn, maar slaapstoornissen kun-
nen ook door pathofysiologische veranderingen worden veroorzaakt. Slaap wordt 
opgedeeld in problemen met in- of doorslapen (insomnie), slaap gerelateerde 
ademhalingsstoornissen (zoals slaap apneu), slaperigheid overdag (hypersomnie), 
slaapstoornissen die van invloed zijn op de biologische klok (circadiane ritme stoor-
nissen), en abnormale bewegingen tijdens de slaap (parasomnieën en slaap gere-
lateerde bewegingsstoornissen).
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derwerpen. 70% van de patiënten had een verstoorde slaap. Er was sprake van een 
significant slechtere slaapkwaliteit bij patiënten die slaap prioriteerden ten opzichte 
van patiënten die slaap niet in hun top 5 zetten. Niet alle patiënten met slaapproble-
men zetten slaap op het lijstje. Het zou kunnen dat voor deze patiënten slaap op het 
moment van bezoek minder belangrijk was dan andere problemen. Opvallend is 
dat patiënten die slaperig zijn overdag, slaap niet vaker op het lijstje zetten dan pati-
enten die hier geen klachten van hadden. Dit komt mogelijk doordat ze slaperigheid 
overdag niet zien als een slaapprobleem. 
Hoofdstuk 3 richt zich op bewegingsproblemen tijdens de nacht. In hoofdstuk 3.1 
beoordeelden we wat de invloed van moeite met omdraaien in bed is voor parkin-
sonpatiënten op de subjectieve slaapkwaliteit, gemeten met slaapvragenlijsten. We 
onderzochten 240 parkinsonpatiënten. 56.3% van de patiënten gaf aan moeite te 
hebben met omdraaien in bed. Slaapkwaliteit was significant slechter in de groep 
parkinsonpatiënten die aangaven problemen te hebben met omdraaien in bed ten 
opzichte van parkinsonpatiënten zonder deze klacht. In hoofdstuk 3.2 beoordelen 
we de invloed van moeite met omdraaien in bed op de objectieve slaapkwaliteit, 
gemeten met PSG. Daarnaast werd onderzocht of patiënten die aangeven moei-
te te hebben met omdraaien in bed ook daadwerkelijk minder positiewisselingen 
maken in de nacht. We vergeleken 44 parkinsonpatiënten met en zonder klachten. 
Verschillende slaapparameters werden geregistreerd middels PSG. Vergelijkbaar 
met onze bevindingen in hoofdstuk 3.1 bleek dat de slaapkwaliteit significant slech-
ter was en totale slaaptijd significant korter bij parkinsonpatiënten die aangaven 
moeite te hebben met omdraaien in bed. Van alle patiënten die deelnamen aan de 
Slaapproblemen bij de ziekte van Parkinson
Circa 90% van de parkinsonpatiënten ervaart problemen met slapen. Gebleken is 
dat gestoorde slaap een belangrijke negatieve invloed heeft op kwaliteit van leven. 
Alle slaapstoornissen zoals boven beschreven kunnen voorkomen bij de ziekte van 
Parkinson. Daarnaast kunnen ook de bewegingsklachten van de ziekte van Parkin-
son de slaap verstoren. De tremor verdwijnt over het algemeen tijdens lichte slaap, 
maar wanneer hij heftig is kan hij de slaap verstoren. Veel parkinsonpatiënten geven 
aan dat ze moeite hebben met omdraaien in bed. Wat hier de precieze oorzaak van 
is, is nog niet precies duidelijk. Allereerst kan de vertraging in het bewegen een rol 
spelen, maar ook de stijfheid kan van belang zijn. Daarnaast kunnen pijnklachten en 
over beweeglijkheid de nacht verstoren. Eerdere studies hebben aangetoond dat 
slechte slaapkwaliteit geassocieerd wordt met moeite met omdraaien in bed. Of pa-
tiënten die aangeven moeite te hebben met omdraaien ook daadwerkelijk minder 
draaien ’s nachts is echter niet bekend. 
Inhoud proefschrift
Hoewel slaapstoornissen veel voorkomen bij parkinsonpatiënten en een belangrij-
ke negatieve invloed hebben op kwaliteit van leven, blijft het vaak een onderbelicht 
onderwerp in de spreekkamer van de neuroloog. Hierbij speelt de tijdsdruk een rol, 
waarbij in korte tijd meerdere facetten van de ziekte moeten worden besproken. 
Daarnaast hebben veel neurologen weinig ervaring met slaapstoornissen, waar-
door ze niet precies weten wat er besproken dient te worden. Hoofdstuk 2 geeft 
inzicht welke slaapproblemen spelen bij parkinsonpatiënten en wat het belang van 
deze problemen is voor de patiënten. Daarnaast leveren we verschillende handvat-
ten om slaapproblemen te detecteren in de spreekkamer. Hoofdstuk 2.1 bevat een 
gedetailleerde introductie over de laatste ontwikkelingen omtrent de herkenning en 
diagnostiek van slaapproblemen bij parkinsonpatiënten. Allereerst ontwikkelden we 
een stroomdiagram dat door iedere neuroloog gebruikt kan worden voor de her-
kenning van slaapstoornissen. Daarnaast geven we adviezen omtrent de verdere 
diagnostiek en geven we aan wanneer een patiënt verwezen dient te worden naar 
een slaapcentrum. In hoofdstuk 2.2 gebruiken we een prioriteitenlijst om vast te 
stellen hoe belangrijk slaap is voor de parkinsonpatiënt zelf. Voor een consult bij de 
neuroloog werd patiënten gevraagd een top 5 te maken van problemen die zij graag 
zouden bespreken met de neuroloog. Van de 153 parkinsonpatiënten zette 37.9% 
slaap op de prioriteitenlijst, hiermee is het het 6e item op een lijst van in totaal 23 on-
Een stroomdiagram kan helpen bij de herkenning van slaapproblemen bij 
parkinsonpatiënten.
Een prioriteitenlijst kan gebruikt worden om verschillende problemen, 
waaronder slaapproblemen vanuit het patiënten perspectief te signaleren.
Elke parkinsonpatiënt met slaapklachten verdient een bezoek aan een 
slaapcentrum.
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we dat parkinsonpatiënten kleinere draaien maakten en de draaien korter duurden. 
De frequentie van het aantal bewegingen en de snelheid was niet veranderd. Om de 
tweede hypothese te toetsen vergeleken we de personen met een hoog risico met 
gezonde controles. Hierbij werden geen verschillen gevonden in de verschillende 
facetten van de beweging. Mogelijk dat deze in een later stadium ontstaan. 
Tot slot bestudeerden we een andere veel voorkomende nachtelijk bewegings-
stoornis bij de ziekte van Parkinson in hoofdstuk 5. Rapid eyemovement (REM) sleep 
behavior disorder (RBD) is een slaapstoornis die zich uit in bewegingen tijdens de 
nacht. Deze bewegingen, treden op tijdens de REM-slaap, die normaal gekenmerkt 
wordt door afwezigheid van spierspanning. Tijdens de REM slaap droomt een per-
soon gewoonlijk. Bij patiënten met RBD lijkt het dan ook vaak of zij op het moment 
van onrust hun droom aan het uitvoeren zijn. Vaak zijn deze dromen agressief of 
beangstigend van karakter. Patiënten maken dan ook vaak slaande of schoppende 
bewegingen. Uit eerdere onderzoeken is gebleken dat personen met RBD later zeer 
vaak de ziekte van Parkinson ontwikkelen. Andersom komt RBD voor bij ca 50% van 
de parkinsonpatiënten. Om de diagnose te kunnen stellen is volgens de criteria een 
duidelijke anamnese het liefst door een slaapdeskundige geïndiceerd, daarnaast 
moet een PSG worden verricht. Dit is echter tijds- en kosten invasief. Er wordt dan 
ook gezocht naar goedkopere en makkelijkere middelen om de diagnose te stellen. 
In het verleden is geopperd om actometers (bewegingsmeters) te gebruiken. Een 
eerdere studie toonde een significante toename van waakperioden bij parkinson-
patiënten met RBD, vergeleken met parkinsonpatiënten zonder RBD. Wij hebben 
deze studie herhaald met een grotere groep patiënten en hebben daarnaast ge-
keken naar een mogelijke afkapwaarde om de patiënten met en zonder RBD in de 
studie werd bepaald hoe vaak zij gedurende de nacht van houding veranderden. 
Weliswaar werd een kleine afname gevonden van het aantal houdingsverande-
ringen gedurende de slaap bij parkinsonpatiënten met klachten, echter geduren-
de de gehele nacht, dus slaap en waak perioden, werd geen significant verschil 
gevonden. Dit is opmerkelijk, zeker omdat patiënten voornamelijk klagen over de 
perioden waarin zij wakker liggen. Tevens werd geen correlatie gevonden tussen 
slaapkwaliteit en aantal houdingsveranderingen gedurende de nacht. Mogelijk dat 
de klacht dus een belangrijkere invloed heeft op de slaapkwaliteit dan het aantal 
houdingsveranderingen zelf. 
Hoofdstuk 4 gaat in op nachtelijke bewegingen in de periode voordat de motore 
klachten van de ziekte van Parkinson aanwezig zijn. Omdat eerdere studies geen 
duidelijk verschil vonden tussen de frequentie van houdingsveranderingen tijdens 
de nacht bij parkinsonpatiënten en gezonde controles, onderzochten we allereerst 
of andere facetten van bewegen ’s nachts zoals de grootte, duur en snelheid van 
de beweging wel verschillend zijn tussen beide groepen. Daarnaast onderzochten 
we of deze veranderingen reeds aanwezig zijn bij personen met een hoog risico op 
het krijgen van de ziekte van Parkinson. We vergeleken de nachtelijke bewegingen 
van 11 parkinsonpatiënten, 13 gezonde controles en 33 personen zonder de ziekte 
van Parkinson, echter met een hoog risico op het ontwikkelen van de ziekte (zoals 
reeds afgenomen armzwaai, reukproblemen, afwijkingen van de hersenstam op 
echo). Bij de vergelijking tussen parkinsonpatiënten en gezonde controles vonden 
Klachten over moeite met omdraaien in bed bij parkinsonpatiënten zijn 
geassocieerd met zowel subjectieve als objectieve afname van slaapkwaliteit.
Parkinsonpatiënten maken niet minder draaien in de nacht, maar de 
houdingsveranderingen zijn wel kleiner en duren minder lang ten opzichte van 
gezonde controles. 
Nachtelijke bewegingspatronen bij personen met een hoog risico op het 
ontwikkelen van de ziekte van Parkinson zijn vergelijkbaar met gezonde 
controles, en lijken daarmee geen duidelijk indicator voor het ontwikkelen van 
de ziekte. Parkinsonpatiënten met klachten van omdraaien in bed, hebben minder 
houdingsveranderingen tijdens hun slaap, maar niet tijdens waak of over de 
gehele nacht.
Slaap lijkt eerder te worden verstoord door het subjectieve gevoel dat 
omdraaien in bed moeilijk gaat, dan door het daadwerkelijke aantal 
houdingsveranderingen tijdens de nacht.
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klisniche praktijk te kunnen onderscheiden. We onderzochten 45 parkinsonpati-
enten en beoordeelden op basis van de officiële criteria of er sprake was van een 
RBD. Alle patiënten kregen hiervoor een PSG, daarnaast kregen ze 8 nachten een 
actometer om, waarvan de eerste nacht gesynchroniseerd werd met de slaaptijden 
van de PSG. Conform het andere onderzoek vonden wij een significante verhoging 
van het aantal waakperioden bij patiënten met RBD. Een afkapwaarde van 95 waak-
perioden resulteerde in een specificiteit van 95.5%, een sensitiviteit van 20.1% en een 
positief voorspellende waarde van 85.7%. Wanneer bij de onderzochte patiënten 
alleen werd uitgegaan van de anamnese werden 7 patiënten onterecht verdacht 
voor RBD. Hiervan hadden er 6 minder dan 95 waakperioden. Dit suggereert dat 
het gebruik van een actometer bij deze patiënten zinvol zou kunnen zijn. Bij eerdere 
onderzoeken over vragenlijsten in het diagnostisch traject van RBD is gevonden dat 
zij een hoge sensitiviteit hebben en een lagere specificiteit. Mogelijk dat een com-
binatie van vragenlijsten en actometers een waardevolle methode zou zijn voor het 
diagnosticeren van RBD. 
Een actometer heeft een toegevoegde waarde naast de anamnese in het 
diagnostisch proces van RBD bij parkinsonpatiënten.
Een afkapwaarde van 95 waakperioden leidt tot een specificiteit van 95.5%, een 
sensitiviteit van 20.1% en een positief voorspellende waarde van 85.7%.
Het gebruik van een actometer toont een hoger aantal waakperioden bij 
parkinsonpatiënten met RBD dan in parkinsonpatiënten zonder RBD.
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De afgelopen jaren ben ik bezig geweest met de verschillende studies die beschre-
ven worden in dit proefschrift, maar ik heb dit natuurlijk niet alleen gedaan. Graag 
zou ik de volgende personen willen bedanken. 
Allereerst natuurlijk Sebas. De afgelopen jaren ben jij een grote inspiratiebron voor 
mij geweest. Zowel als onderzoeker als ook met je kennis van de klinische slaapge-
neeskunde. Ik was steeds trots als ik de andere studenten van de ESRS trainingen 
kon vertellen dat jij mijn begeleider was. Zeker toen tijdens mijn stage in Bologna het 
grootste gedeelte van de presentaties refereerden naar jou onderzoeken. We waren 
het niet altijd met elkaar eens, en soms kon je het bloed onder mijn nagels vandaan 
halen, maar ik denk dat dat mij de afgelopen jaren niet alleen een betere onderzoeker, 
maar ook een sterker persoon heeft gemaakt. Ik heb geleerd dat ik met goed on-
derbouwde argumenten een heel eind kan komen. Bedankt voor de samenwerking!
Beste Bas. Al tijdens mijn studie raakte ik geïnspireerd door jou enthousiasme 
voor de neurologie. Dit was een van de reden om te kiezen voor dit vakgebied. Het 
doen van promotieonderzoek met jou als promotor was dan ook een voorrecht. 
Ook tijdens onze samenwerking bleef ik steeds onder de indruk van jou gave om 
onverwachte resultaten te interpreteren naar de kliniek en steeds nieuwe ideeën 
te hebben voor onderzoeken. Jouw uitgebreide klinische ervaring en expertise in 
combinatie met onderzoekskwaliteiten zijn van grote invloed geweest op de kwali-
teit van mijn onderzoek. 
Beste Dirk. Als slaapgeneeskundige, niet alleen bekend in Nederland en België, 
maar wereldwijd, was jou toevoeging tot mijn promotieteam zeer welkom. Zowel als 
wetenschapper als als clinicus heb ik ontzettend veel van je geleerd de afgelopen 
jaren. Jouw kennis van de slaapgeneeskunde heeft mijn onderzoek naar een hoger 
niveau gebracht. 
Beste Johan, als epileptoloog lijkt jou rol in mijn promotietraject wellicht wat vreemd 
voor anderen. Echter jou eerdere ervaringen binnen de slaapgeneeskunde in com-
binatie met jouw expertise op het gebied van bewegingsdetectie zijn echter van 
groot belang geweest voor mijn onderzoek. Daarnaast zetten jouw kritische vragen 
mij altijd weer aan het denken tot een verbetering van mijn onderzoek. De promotie 
tot professor tijdens mijn onderzoeksperiode, was dan ook niet onverwacht. 
Buiten mijn directe begeleiders waren er meerdere samenwerkingsverbanden met 
andere personen en instituten, die ik graag zou willen bedanken. 
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Werkend binnen zowel Kempenhaeghe als het Radboud heb ik veel contact gehad 
met andere promovendi op beide instituten. Ik wil zowel de onderzoekers van ParC 
als de promovendi op de Boondert bedanken voor alle gezellige etentjes, Sinter-
klaasvieringen, uitstapjes en lunches. Hierbij wil ik vooral Marjolein en Maaike noe-
men aan wie ik tijdens mijn dagen in Nijmegen veel heb gehad. Zowel op als prak-
tische hulp bij het onderzoek als ook vanwege alle gezelligheid tijdens deze dagen.
Mijn dank gaat ook uit naar alle collega’s in het MCHaaglanden, die mij alle ruimte 
hebben gegeven om mijn promotieonderzoek af te ronden, maar ook nieuwe stu-
dies te starten. Bedankt dat jullie in mij geloven.
Ook wil ik mijn directe omgeving bedanken, met name mijn ouders. Lieve Baas en 
Margreet. Opgegroeid in een wetenschappelijk nest was een stap naar een promo-
tieonderzoek natuurlijk niet geheel onverwachts. Bedankt voor de steun die jullie 
de afgelopen jaren altijd hebben gegeven. Maar ook mijn broertje, schoonfamilie, 
aanleun schoonfamilie en vrienden. Bedankt voor alle steun, maar ook fijne afleiding 
de afgelopen jaren. 
Last but not least, Bart. Al ruim 10 jaar ben jij het rustpunt in mijn leven. Hoe gefrus-
treerd, boos, verdrietig of blij ik ook ben jij kunt mij altijd weer met beide benen op 
de grond zetten. Altijd kon ik bij jou terecht over dingen die mij bezighielden tijdens 
mijn onderzoek. Geïnteresseerd luisterde je naar mijn bevindingen, hoewel je de 
helft van de tijd niet begreep wat ik bedoelde. Dacht ik, want je wist altijd met een 
goede vraag te komen. Bedankt dat je er de afgelopen jaren altijd voor me was in 
goede en in slechte tijden. Lieve Tijn, vlak nadat jij werd geboren stuurde ik mijn 
manuscript naar de commissie. Je hebt dus niet veel mee gekregen van het hele 
proces. Ik zal je er later meer over vertellen.
First of all I would like to thank the people of the Hertie Institute for Clinical Brain Re-
search in Tubingen university, especially Inga Liepelt-Scarfone and Walter Maetzler. 
I was a privilege working with you. I think our collaboration led to a very nice study.
Daarnaast wil ook de medewerkers van McRoberts bedanken voor de samenwerking, 
met name Rob van Lummel en Jos Prinzen. Rob, het was fijn samen te werken en 
te denken hoe we de bewegingen van onze patiënten het beste konden vastleggen 
met de Dynaport. Jos, bedankt voor de hulp bij de analyse van de data. Wanneer 
ik weer mailde met de vraag dat ik het toch net iets anders wilde, dan stond je altijd 
klaar om weer aanpassingen te verrichten. 
Vervolgens wil ik Pierre Cluitmans en Ruud van Sloan van de Technische universiteit 
Eindhoven bedanken voor hun medewerking aan het stuk over impaired bed 
mobility. Zonder jullie expertise en analyse was het niet zo’n goed stuk geworden. 
Bedankt voor de samenwerking. 
Natuurlijk wil ik ook alle medewerkers van het CSG Kempenhaeghe bedanken. Lieve 
behandelaars, secretaresses, slaapverpleegkundigen en KNF-laboranten bedankt 
dat jullie de aflopen drie jaar zulke leuke collega’s waren. Als fulltime onderzoeker 
binnen het CSG was ik een beetje een vreemde eend in de bijt, maar als snel hebben 
jullie mij meer dan welkom laten voelen. 
In het bijzonder wil ik binnen Kempenhaeghe Petra bedanken. Mijn eerste dag op 
Kempenhaeghe had jij de taak mij rond te leiden in de wondere wereld van het on-
derzoek. Als onderzoeksverpleegkundige was jij net zo’n rare binnen het CSG als ik. 
Al snel werd je mijn kamergenote waardoor we jaren lief en leed hebben gedeeld 
zowel over het werk als ook in ons privéleven. Bedankt voor alle leuke momenten, 
goede gesprekken en afreageersessies.
Ook mijn beide paranimfen verdienen een aparte plek. Merel, wat was het leuk toen 
jij werd aangenomen als promovenda op hetzelfde onderwerp als ik. Eindelijk ie-
mand in de omgeving met wie ik kon sparren over het onderwerp en samen con-
gressen kon bezoeken. Bedankt voor je luisterend oor, maar ook gezellige momen-
ten met name tijdens ons bezoek aan SLEEP in Boston. Helaas zagen we elkaar 
door verschillende werkplekken maar twee dagen in de week, maar die waren zeer 
waardevol. Marye, jij hebt als vriendin een speciale rol, omdat jij tegelijk met mij ook 
bezig was met promotieonderzoek. Ik kijk dan ook met veel plezier terug op onze 
lunches op de donderdag. 
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